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Abstract
This work details the development of two distinct prototype point-of-care
diagnostic systems to be used to determine the efficacy of anti-platelet ther-
apies. Novel microfluidic chips were designed for each system, to enable the
on-chip testing of multiple anti-platelet therapies. The prototypes work
with whole blood and integrate with a new detection method used to de-
termine the percentage of platelets adhered to an array of fibrinogen spots.
The system uses customised image analysis software to objectively quantify
single platelet binding events from a single blood sample, without the need
to add any form of labelling to the blood. The system was validated by
comparing the percentage of platelets adhered from ‘normal’ blood samples
compared to samples treated with an established platelet therapy. These
treatments inhibit a specific receptor on the platelet surface, thus inter-
fering with stable adhesion to fibrinogen, rendering platelets “less sticky”.
This prototype point-of-care device could allow for the automated testing
of large numbers of patient samples, potentially diagnosing individuals at
risk of suffering a cardiovascular event or undiagnosed bleeding disorder.
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Chapter 1
Introduction
Cardiovascular disease (CVD) is the leading cause of death and disability
in the world [1], within the EU alone 1.9 million deaths were attributed to
CVD with an estimated cost to the economy of almost 196 billion Euro a
year [2]. 54% of this 196 billion is due to health care costs, 24% due to
productivity losses and 22% due to the informal care of people with CVD
[2]. Individuals with high blood pressure, high cholesterol, obesity, physical
inactivity, unhealthy diets and diabetes all have an increased chance of
developing CVD and thereby suffering a cardiovascular event [3]. Heart
attack and stroke are the most prevalent cardiovascular events and occur
as a result of the formation of thrombosis i.e. a clot that blocks the flow of
blood in the heart or brain.
Individuals at increased risk of suffering a cardiovascular event such as
a heart attack or stroke are routinely treated with anti-platelet therapies
such as acetylsalicylic acid (Aspirin), while clopidogrel (Plavix) is also used
alongside Aspirin for the prevention of thrombosis after placement of a in-
tracoronary stent [4]. Although clopidogrel is a highly effective anti-platelet
therapy, it has been shown that there is a wide inter-individual variability of
response to clopidogrel, with about one-third of patients treated exhibiting
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a suboptimal inhibition of platelet function (increasing the risk of thrombo-
sis) [5]. The ability to tailor drug treatments based on the results of a cost
effective, standardised and clinically relevant device for testing of platelet
function, could reduce the risk of cardiovascular events in at-risk groups [6].
There is potential for anti-platelet tests to be used for diagnostic appli-
cations, where test results may indicate further investigation or treatment
with an antiplatelet therapy is required. Devices have been demonstrated
that can monitor platelet function but to date these assays are utilised
as laboratory research tools and have not being adequately developed for
point-of-care use [7, 8].
1.1 Platelets
The human platelet has approximate dimensions of between 2 µm to 4 µm
by 0.5 µm. Their mean volume is between 7 fL and 11 fL. [9]. Platelets are
the second most numerous corpuscles in whole blood with between 150 and
450 × 109 per litre, in a normal sample of blood. Platelets are anucleated
cells that typically circulate for 10 days. Whole blood platelets tend to
concentrate near the wall while red blood cells (RBC) remain in the centre
of the flow [10]. This places the platelets at the optimum location to respond
to damage at the vessel wall, allowing for the formation of a haemostatic
plug or thrombus [10].
1.1.1 Platelet Response to Vascular Injury
Platelets play a vital role by stemming blood loss (haemostasis) and initi-
ating tissue healing in response to damage to the endothelial cells that line
the vascular wall. Platelets within a healthy individual circulate through
the blood vessels, without the need to interact with one another or with the
2
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vascular wall. The term haemostasis comprises all the acute response mech-
anisms that are initiated to stop bleeding when blood vessels are damaged.
During the primary haemostatic response there are three distinct stages
a platelet will pass through, Activation, Adhesion and Aggregation. Fig-
ure 1.1 shows a cross-section of a blood vessel with both red blood cells and
circulating platelets highlighted. When a platelet comes into contact with
an area of damaged endothelial cells, surface receptors cause the platelet
to become activated. Once the platelet is activated, it will adhere to the
damaged area and begin to recruit more circulating platelets that in turn
start to aggregate, thereby beginning the formation of a haemostatic plug.
GPmIb/IX/V
VonmWillebrandmFactor
GPmVI
Collagen
GPmIIb/IIIa
GPmIIb/IIIa
Flow
Circulating
platelet
Endothelialmcell
Rolling\Translocate
platelet
Endothelial
damage
Redmbloodmcell
Activatedmplatelet Adheredmplatelet Aggregatingmplatelets
Figure 1.1: A cross-section of a vessel with vascular damage showing platelets
in their different states of response seen during vascular injury.
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Activation
When damage occurs at the wall of the blood vessel Von Willebrand Factor
(VWF) becomes exposed on the surface of the damaged sub-endothelium.
Platelets are initially bound to this damaged surface via interactions be-
tween VWF and Glycoprotein (GP Ib/IX/V) resulting in the activation of
the platelet [11]. The interaction between the platelets and damaged en-
dothelium slows the platelets and causes a characteristic translocating or
rolling of the platelets along the damaged surface (Figure 1.1).
Adhesion
Platelet adhesion plays an important role in normal platelet haemosta-
sis whereby platelets will adhere at sites of vascular damage, disruption,
endothelial dysfunction, and exposed sub-endothelial collagen or lipid de-
posits. These areas can be found in ruptured or eroded atherosclerotic
plaques [11, 12]. Specific platelet membrane glycoproteins are recognised
by the adhesive protein Collagen and allow the platelets to adhere when
Collagen becomes exposed within the vessel wall and interacts with the
platelet receptor GP VI ( Figure 1.1).
Aggregation
Glycoproteins are also critical for cell−cell interactions as a change in the
membrane receptor GPIIb/IIIa allows fibrinogen to form multiple cross-
links between GPIIb/IIIa on adjacent platelets (Figure 1.1) [13]. The for-
mation of a haemostatic plug at sites of vascular damage is started by
the recruitment of circulating platelets and continues until the plug is fully
formed. A lattice of fine fibrin acts to reinforce the plug against the pressure
of the blood and starts to stem blood loss. Pathologic thrombosis occurs
4
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when this process is affected by disease, leading to life threatening events
such as acute myocardial infarction and deep venous thrombosis.
1.1.2 Anti-Platelet Therapies
The surface of a platelet is covered in a variety of receptors which bind to
specific molecules during the different stages of haemostasis. Anti-platelet
drugs can block these receptors, thus reducing thrombus formation. Clopi-
dogrel (Plavix) is an anti-platelet drug that blocks the P2Y12 receptor and
is used for the prevention of thrombosis after placement of an intracoronary
stent [11]. By testing platelet adhesion or aggregation a measurement of
platelet function can be determined and thereby a measure of the efficacy
of the anti-platelet therapy. With a number of studies showing the response
to an anti-platelet drug may vary from patient to patient [6], there is a need
for a reliable, reproducible and cost effective test to measure an individual’s
response to these drugs.
1.2 Platelet Function Analysis
Many of the well-established platelet function tests were designed for the
diagnosis and treatment of bleeding disorders. The most common assays to
evaluate anti-platelet drug effects, including flow cytometry and the gold
standard, light-transmission platelet aggregometry, are mainly restricted to
specialised facilities and require the sample to be processed before use [14].
While a small number of automated devices that work with whole blood
are available, they are mainly restricted for laboratory use only and are not
routinely used as a point-of-care test (POCT) [15]. A POCT can be defined
as medical testing at or near the site of patient care.
5
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Bleeding Time
First used by Duke in 1910, bleeding time is the time it takes for a stan-
dardised skin cut of fixed depth and length to clot [16, 17]. Bleeding time
is not a useful predictor of the risk of haemorrhage (uncontrolled bleeding).
Patients who may have recently taken aspirin or anti-inflammatory agents
cannot be reliably identified using bleeding time. By the 1990s bleeding time
had been replaced by light transmission aggregometry as the gold standard
for the diagnosis of platelet disorders [18].
Light Transmission Aggregometry
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Figure 1.2: Light Transmission Aggregometry
Light transmission aggregometry (LTA) is a laboratory based technique
invented in the 1960s and is currently the gold standard for the measurement
of platelet function [11]. LTA requires a whole blood sample to be processed
to create platelet rich plasma (PRP) and platelet poor plasma (PPP). Whole
blood is centrifuged at 170-200 g for 10 minutes to create the PRP, while
PPP is prepared by centrifugation (after removal of PRP) at a minimum of
6
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1500 g for 15 minutes [19]. Platelet aggregation is calculated by passing a
beam of light through the PRP. The amount of light to pass through the
sample is detected with the use of a silicon photodiode, with the change in
the percentage of light transmitted through the sample corresponding to the
rate at which the plasma is aggregating or disaggregating. Figure 1.2 shows
a standard aggregation curve with both the PPP and PRP reference levels
shown, with the slope of the curve between these two points indicating the
rate of platelet aggregate formation. The PPP reference level indicates the
maximum light that can pass through the PRP after an agonist has been
added. The PRP is stirred continually whilst testing is taking place, as
the absence of stirring will lead to a significant reduction in aggregation.
When an agonist is added there is an initial drop in the transmission of
light below the PRP reference before the agonist is absorbed into solution
and aggregation begins. Figure 1.2 shows an ideal curve and assumes 100%
aggregation after a given time, in reality the aggregation will plateau at a
maximum value for the sample being tested.
LTA has a number of limitations as a technique for use within a point-of-
care device as it requires a specialised laboratory with specialised personnel,
is time-consuming, expensive and needs the blood to be processed. The
preparation of both PRP and PPP requires a minimum of 25 minutes and
the use of a centrifuge before the plasma is manually separated from the
whole blood sample. The results from a single sample can depend on the
device used and the laboratory at which they were processed. The high
level of manual handling of blood, training required and equipment costs
also make the test impractical as a point-of-care device.
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PFA-100©
Platelets mainly bind to subendothelial collagen exposed upon vascular in-
jury and can bind directly to the exposed collagen through two major recep-
tors; the integrin α2β1 and glycoprotein GPV I. This binding takes place
at shear rates > 1500 s−1. Two examples of platelet function assays at work
at high shear rates are the Analyzer-100 (PFA-100©) and the Impact-R©
cone and plate(let) [11, 15].
Vacuum
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Blood 
Sample
Sample
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Coated
Membrane
Vacuum
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Flow
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Figure 1.3: PFA-100©
PFA-100© uses a single use membrane that can be coated with collagen
and epinephrine (CEPI) or collagen and ADP (CADP). Figure 1.3 shows
a cross-section of the PFA cartridge alongside a photo of the device. The
enlarged area shows the whole blood sample been drawn from the reservoir
and aspirated into a capillary and through a 147 µm aperture cut into the
membrane. A negative pressure is then applied to the sample to achieve flow
at a shear rate of between 5000 and 6000 s−1, as a haemostatic plug is formed
across this aperture [14]. The amount of time required for the occlusion of
the aperture by the haemostatic plug is regarded as the measurement of
platelet function in this assay. Von Willebrand disease (VWD), primary
secretion defects (PSD), Hermansky-Pudlak syndrome, (HPS) and storage
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pool disease (SPD) are not related to platelet function, but may affect the
time for the haemostatic plug to occlude the aperture [20]. PFA-100 has a
limited use when trying to detect the specifics of platelet function as these
disorders are not related to platelet function but can affect the ”time-to-
plug”. The device is also limited to testing only one agonist at a time and
requires the blood to be pipetted into the sample reservoir of a cartridge.
The PFA-100 is therefore a single agonist test that requires manual blood
handling, making it better suited for laboratory use only.
Cone and Plate(let) Analyser
The cone and plate(let) analyser was originally developed by Varon and
monitors platelet adhesion and aggregation to a plate coated with collagen
or extracellular matrix (ECM) under high shear conditions of 1800 s−1. A
commercial version was later developed by DiaMed [11].
(A ) (B ) (C ) (D )
Blood Stain And Wash
Cone Imaging
Plate
Figure 1.4: (A) Whole blood is first loaded into the well.(B) The cone is lowered
into the well and rotated and the blood sheared. (C) The plate is then washed
and the platelets stained. (D) The platelets can now be imaged.
Figure 1.4 shows the principle behind the cone and plate system. Whole
blood is first loaded into the well covering a plate coated with extracellular
matrix (ECM) before a cone is lowered into the well and rotated in order
to shear the blood. After a fixed time the plate is removed, washed and
the adhered platelets stained to allow for imaging. Although the Impact-
R© (DiaMed) is a commercially available cone and plate(let) analyser, the
system still requires the use of trained personnel and therefore remains a
9
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tool for specialist use only [14]. Platelet adhesion in this assay is only read
at one time point and as platelet adhesion is a dynamic process potentially
useful clinical data could be lost by taking only one reading.
VerifyNow©
VerifyNow© is an automated cartridge-based system available for the test-
ing of anti-platelet therapies in the clinic. The system tests a whole blood
sample for its response to anti-platelet agents such as Clopidogrel GP IIb/IIIa
inhibitors.
B
lo
o
d
Protective 
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Sample 
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Grip
Figure 1.5: VerifyNow© cartridge
The VerifyNow system is based around a single-use cartridge shown
in Figure 1.5 and works with the BD Vacutainer (Becton, Dickinson and
Company) also shown in Figure 1.5. The Vacutainer is a sterile glass or
plastic tube with a vacuum inside, the vacuum facilitates the draw of a
blood sample. Figure 1.6 shows the operation of the cartridge once it had
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Figure 1.6: (A) vacutainer is connected. (B) A vacuum pumps the blood into
the staging well. (C) Blood is moved from the staging well into the detection
wells. (D) Blood is mixer bead to help the aggregation of platelets.
been connected to the VerifyNow system. A full Vacutainer is inserted into
the cartridge through the use of the Vactainer spike. The VerifyNow device
applies a vacuum to pump the blood into the staging well at the right of
the cartridge. The blood is heated before the pressure is reversed and the
blood is moved from the staging well into the detection wells. A fibrinogen
bead within the detection wells dissolves into the blood before a magnetic
mixing bead, contained in the wells, is moved in order to mix the blood and
help the aggregation of platelets. After mixing is complete, light is passed
through each of the detection wells and measurements are taken before the
system can return an output value in platelet reaction units (PRU). The
ability of the assay to use whole blood and the automated test platform give
the system a number of advantages over LTA. However, the inflexibility of
the cartridge allows only one therapy to be tested at a time with a separate
Vacutainer (10 ml) of blood required for each test.
Two large scale studies have been undertaken using the VerifyNow sys-
11
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tem [21, 22]. The Gauging Responsiveness with a VerifyNow P2Y12 assay:
Impact on Thrombosis and Safety (GRAVITAS) and The Bedside Monitor-
ing to Adjust Antiplatelet Therapy for Coronary Stenting (ARTIC). The
GRAVITAS trial enrolled 5429 patients with coronary artery disease (pre-
dominantly, albeit not uniquely, with stable disease) [22]. The trial found
that using VerifyNow to test platelet function did not affect the primary
end point of cardiovascular death, myocardial infarction or stent thrombo-
sis and the determination of a suitable clinically relevant cut-off level using
the VerifyNow was challenging. The ARTIC studies randomly assigned 2440
patients scheduled for coronary stenting to a strategy of platelet-function
monitoring [21]. The study found no significant improvements in clinical
outcomes when using the VerifyNow system for platelet-function monitor-
ing [21].
1.2.1 Summary of Devices
A communication by the scientific and standardisation committee of the
International Society on Thrombosis and Haemostasis [23], reported a series
of points highlighting the issues with use and development of the current
flow tests used to evaluate bleeding risk. These points include:
1. Use and quantity of controlled collagen as adhesive substrate
2. Time-dependent measurement of thrombus build-up
3. Use of non-anticoagulated blood, preferably at physiological cation
concentrations
4. Use of single-pass, small capacity flow devices
While the list was specifically generated with a view towards VonWille-
brands disease, many of the points are of a generic nature and can be applied
12
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to many platelet function assays. Each device in this section was examined
for their use as a point-of-care device for testing the effectiveness of anti-
platelet therapies and compared against the above list. The review showed
that while many of the devices have a number of advantages there are still
many challenges to overcome. Although LTA remains the gold standard for
the testing of platelet function, the requirement to centrifuge the blood in
order to create PPP and PRP, and cost of ownership makes LTA unsuitable
as a point-of care (POCT) device. With the possibility that more than
just platelet function may affect the results from the PFA-100, the device
is better suited to a laboratory where additional testing is available. The
VerifyNow © system goes a long way towards meeting the needs of any pos-
sible POCT device. However, it is still mainly used as a laboratory tool due
to its relatively high cost. Many patients are on dual anti-platelet therapy
requiring more than one cartridge per patient, making this assay costly and
may preclude the VerifyNow © being used as a part of routine screening.
Furthermore, two large scale studies also report no significant improvements
in clinical outcomes when using the VerifyNow © system. It is clear from
this review that at present there is no suitable POCT currently available
for the testing of platelet function, and continued research into this area is
required if one is to be developed.
1.3 Individual Platelet Adhesion (iPA)
Individual Platelet Adhesion (iPA) allows for the adhesion of a single platelet
onto a 6 µm fibrinogen dot. Whole blood is incubated at room temperature
for 30 minutes and rocked at 35 oscillations per minute. While iPA has
been successfully demonstrated for the monitoring of patients undergoing
anti-platelet therapy it has not yet been integrated into a chip [24].
For this thesis the iPA assay was used, as a starting point, for the re-
13
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search and development of two prototype devices that have both success-
fully integrated the iPA assay. The first device is based on degas-driven
flow, detailed in Chapter 4. The second prototype takes advantage of the
rocking-table to create flow across the fibrinogen dots, detailed in Chapter
5.
Protein array
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Figure 1.7: Whole blood is incubated on a substrate array of platelet-specific
protein. Single platelets adhere to the protein spots, creating arrays of single
platelets on the substrate and the percentage adhesion is quantified by use of
fluorescence microscopy.
A novel method for the measurement of platelet function has recently
been demonstrated by Basabe-Desmonts et. al. This method allows for
separation of individual platelets from whole blood. As only a single platelet
binds to a spot a digital quantification of platelet function is possible [25].
1 mL of citrated whole blood is placed covering the protein patterned
surface and incubated for 30 minutes. The blood is rocked to prevent other
blood cells from blocking the protein spots. Once incubated the slide is
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washed and the platelets labelled (Figure 1.7) [25]. Using fluorescence mi-
croscopy the now labelled platelets can be counted and the percentage ad-
hesion calculated. The use of this assay for the monitoring of patients
on both dual and single anti-platelet therapies was demonstrated by Ana
Lopez-Alonso et. al. [24].
1.3.1 Labelling Used Within iPA Assay
Incubate3with3platelet3
specific3antibody3mouse3
anti-CD413for31hr.
Incubate3with3
Alexa3488-labelled3
anti3mouse3antibody
Image3under3cy33filter3to3
observe3fibrinogen3printing3
Image3under3FITC3filter3
to3observe3platelets
PDMS3stamps3were3inked3
with3503μL3of3a32003μg/mL3
fibrinogen3solution
1 2
Figure 1.8: Use of labelling within the iPA assay. 1) cy3 label used to label
the 6 µm fibrinogen spots, arrayed in squares of 13 × 13. 2) Image of platelets
adhered to spots, labelled with Alexa-488 and visible under FIFC filter.
Figure 1.8 shows the labelling techniques used as part of the iPA as-
say. Fibrinogen is mixed with Cy3 labelled bovine serum albumin (BSA,
25 µg/mL) before being applied to a PDMS stamp and µ-contact printed
onto the selected substrate. Labelling of platelets bound to the fibrinogen
spots takes place after the assay has been run and the substrate washed.
This is achieved by first incubating with a platelet specific antibody (mouse
15
P. M. McCluskey
anti-CD41) for 1 hour before incubating with a secondary Alexa-488 labelled
anti-mouse antibody for 30 minutes. The Alexa-488 dye has an excitation
value of 495 nm and an emission value of 519 nm.
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Figure 1.9: Excitation and emission wavelength values for fluorescent dyes uses
as part of the iPA assay, Alexa-488 and Cy3 are shown.
Figure 1.9shows the excitation and emission for both Alexa-488 and
Cy3. Alexa-488 dye (platelet image) has an excitation value of 495 nm and
an emission value of 519 nm and Cy3 dye (fibrinogen spots image) has an
excitation value of 550 nm and an emission value of 570 nm. The emission
value for the fibrinogen spots is far enough away from that of the platelets
to allow for two separate images to be produced, with the use of a suitable
filter. The protein array is shown in red (Figure 1.8) while the platelet
image is shown in green; by matching each platelet to a protein spot the %
of occupied spots can be calculated.
1.4 Microfluidic Channels And MEMS De-
velopment
A microfluidic channel can be defined as having one or more of its dimen-
sions less than 1 mm, and the volume of the channel can be as little as a few
nanoliters [26]. This allows for a small sample size, reducing the amount
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of reagents used when compared to traditional devices. These reductions
often lower the final device cost, particularly when expensive reagents are
used [27, 28]. Fluids used within these devices include, bacterial cell sus-
pensions, protein and antibody solutions. Whole blood can also be used
within these devices with properties such as temperature, red blood cell
count, and clotting factors effecting how a blood sample can flow through
a microfluidic channel. The flow characteristics of blood must therefore be
considered when designing the channels used within this project.
Re =
inertialforces
viscousforces
=
ρVavgL
µ
(1.1)
The Reynolds number, Re, is a dimensionless number (Equation 1.1),
given the ratio of inertial forces to viscous forces and plays an important
role in the design of microfluidic devices. The Re is also used to characterise
the type of flow within a channel as laminar for values less than 1500 and
turbulent for values over 2500, while for Re values between 1500 and 2500
the flow is considered to be transitioning between fully laminar and fully
turbulent [29]. For microfluidic channels the Re is generally less than 100,
allowing for flow in a microfluidic channel to be considered as laminar.
It is generally assumed that the no-slip boundary condition can be ap-
plied once the flow is laminar and pressure driven. However, this assumption
may not be valid within a microfluidic channel with complex behaviour at
a liquid/solid interface where wetting, shear rate, pressure, surface charge,
surface roughness, impurities and dissolved gas may challenge this assump-
tion [30]. This boundary condition allows for a simplification of the equa-
tions, by assuming the fluid velocity at the walls is zero. The importance
of these assumptions are further developed in Chapter 2.
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MEMS
Microelectromechanical systems (MEMS) are defined as having both minia-
turised mechanical and electromechanical elements that can be fabricated
using micro-fabrication techniques such as photo lithography, chemical vapour
deposition, plasma enhanced chemical vapour deposition and sputtering
[31]. Mechanical machining and laser ablation can also be used to fabricate
MEMS. Mechanical machining of MEMS can be used when fabricating pro-
totype devices or a small number of commercial devices, with the cost of
equipment and the time required to machine each device making it imprac-
tical for large scale production. While micro-machining methods such as
photo lithography allows for large volumes of devices to be fabricated the
cost of setup can make it unsuitable for small volumes. MEMS have been
developed since the 1970s for use in devices such as pressure sensors, tem-
perature sensors, accelerometers, altimeter and gas chromatography. The
mobile phone is an example of the advances in MEMS enabled devices from
its microwave transmitter to the touch-screen used on smartphones, indi-
cating how MEMS devices play an ever-increasing role in daily life [32].
The dimensions of a MEMS device can vary from well below one micron to
as big as several millimetres. The types of MEMS devices can vary from
relatively simple structures having no moving elements to devices with a
high level of complexity and millions of moving parts such as complemen-
tary metal-oxide-semiconductor (CMOS) used in computer memory [33].
MEMS devices that integrate microfluidic channels are also available and
are widely used within both the laboratory and the clinical environments.
As the Reynolds number within a microfluidic channel is very low and the
flow is almost always laminar mixing of the sample can be difficult, as mix-
ing is only through diffusion across the streamlines. The design of any
microfluidic device will need to allow time for mixing, if the assay requires
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the blood to be mixed with a reagent before testing.
MEMS microfluidic devices have the potential to be of use as a point-of-
care device when they over an advantage over traditional flow based devices,
where per-unit cost, automation or the cost of reagents play a key role [28].
Devices designed to miniaturise analytical or bioanalytical techniques by
integrating them into a micro-fabricated format are generally included under
the umbrella term Lab-on-a-Chip (LoaC)
BioMEMS
Bio-Microelectromechanical (BioMEMS), with a focus specifically on bio-
logical applications can be considered to be LoaC devices. LoaC devices are
typically advantageous because they have:
 low fluid volumes required, because of the low internal chip volumes.
 safer platform for biological, chemical or radioactive samples(only a
small sample volume is required).
 higher analysis and control speed of the chip.
 better efficiency due to short mixing times (short diffusion distances).
 faster heating as a result of short distances, high wall surface-to-fluid
volume ratios and small heat capacities.
 compactness of the systems due to large integration of functionality
and small volumes.
 lower fabrication costs, allowing for mass-produced and cost-effective
disposable chips.
BioMEMS is a rapidly growing area of MEMS and uses some of the
same micro-fabrication technologies as MEMS. BioMEMS allows for the
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integration of microfluidic channels and sensor(s) onto a single chip that
can be fabricated reproducibly using current available technologies [34].
Implantable devices such as retinal implants, systems to deliver drugs and
devices for the stimulation and recording of the central nervous system are
amongst only a few possible applications being developed using BioMEMS
[35]. Point-of-care devices could also benefit from the on-going development
of BioMEMS.
1.4.1 BioMEMS for Cell Based Analysis
Many BioMEMS devices aim to reduce the cost and sample size of current
and future cell-based assays. Relatively inexpensive MEMS technology is
ideal for use in the next generation of cell culture and cell analysis tools
where large numbers of single cells or small cell populations can be inves-
tigated in a cellular microenvironment of increased physiological relevance,
when compared to current methods [36]. There are currently a significant
number of MEMS-based flow devices available across a number of different
applications [37, 37–39]. A common flow chamber design used in cell-based
MEMS is known as a parallel plate flow chamber.
Parallel Plate
Parallel plate flow chambers are the design of choice for many applications
where the shear effects on biological species play an important role. A
significant body of work has already been carried out on the effect flow
conditions can have on assays, where shear rate is an integral part of the
assay design [40–42]. A body of work has also been developed, investigating
the implications of adjusting variables such as aspect ratio, entrance length
and inlet design on overall performance of a parallel plate flow device [43–
45]. The combination of these research areas allow for the design of parallel-
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plate flow chambers where the fluid behaviour can be readily understood
and modelled. The low aspect ratio of parallel plate flow chambers is a
key consideration in their design, where the width of the channel (b) is
far in excess of the height (a) allowing for a significant simplification of the
governing equations and making any calculations for shear relatively simple.
This is further explained in Chapter 2.
1.5 Fabrication
For a Lab-on-a-Chip device to be practical, its fabrication must be both
rapid and reproducible. MEMS devices were predominantly silicon-based
[46], allowing both rapid and reproducible fabrication. However silicon’s
lack of optical transparency makes it unsuitable for MEMS devices where
imaging of a surface is required. The ability to fabricate MEMS using
an optically transparent medium is particularly important in the area of
BioMEMS, where the facility to make use of optical detection strategies and
microscopy measurements make a transparent medium of significant advan-
tage. Once modified, many of the existing semiconductor techniques could
be applied to a glass substrate, allowing optically transparent BioMEMS to
be fabricated. Glass is well suited as an optically transparent substrate, as
it is both chemically and biologically compatible. These devices are often
a single-use item and have proved relatively expensive for mass fabrication.
There is a need for methods to manufacture multiple devices reproducibly,
with a short lead time and at a low cost. Polymers offer an alternative to
glass and have become popular for use as material for BioMEMS or Lab-on-
a-Chip devices [47, 48]. Polymers are available in a wide range of low-cost
biochemically compatible materials, each with different characteristics that
are relatively easy to process and prototype, giving polymers a number
of advantages over silicon or glass. The manufacturing of polymer-based
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devices can be divided into two distinct subgroups, direct or replication
techniques.
Direct and Replication Techniques
Direct-machining typically involves the removal of material in order to pro-
duce the desired pattern; in the case of MEMS devices this pattern is defined
by the network of fluidic channels of a controlled depth and width. Typi-
cal polymer direct-machining techniques involve micro milling [49] or laser
writing [50] and allow for flexible and offer short lead times making them
particularly suited to prototyping of MEMS devices. Replication techniques
typically involve the fabrication of a relatively expensive master which will
be used to produce all subsequent devices. The master typically needs to
be of a high quality and finish. The manufacture of the master may in-
clude using traditional machining techniques such as milling or turning,
photolithographic techniques may also be considered. Common methods of
replication include embossing [49, 51, 52], injection moulding [53, 54], or die
cutting techniques. Once in use, the masters may also wear out and need
to be replaced. Although there is an initial investment, in both time and
increased cost, needed to manufacture, a master the cycle time (per device)
is typically significantly shorter than direct machining. This can make repli-
cation better suited to production of a large number of devices or where the
cost or lead time of direct machining techniques proves prohibitive.
Photolithography
One of the most widely used fabrication techniques for the manufacture
of microfluidic channels is photolithography. The process starts with an
opaque plate (photomask) on which a transparent pattern has been made
so that light can only pass through the pattern; these geometric patterns
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Figure 1.10: Steps required to fabricate microfluidic channels using photolithog-
raphy. (1) The wafer is cleaned and readied for use in photolithography. (2) A
photoresist is then deposited onto a substrate. (3) The mask is applied along
with a light source, to transfer the pattern onto the wafer. (4) Development. (5)
Etching. (6) Resist removal.
layout the path of the channels to be created. A wafer, normally silicon, is
prepared by first cleaning away any organic or inorganic contaminants, be-
fore a light-sensitive chemical (photoresist) is spin-coated onto the surface.
Ultraviolet excimer lasers are widely used as a light source in photolithog-
raphy and operate at 248 nm (krypton fluoride laser) and t 193 nm (argon
fluoride laser). The light is passed through the photomask transferring the
channel design onto a photoresist before a chemical treatment is then used
to engrave the exposed pattern into a base material beneath (Figure 1.10).
Photoresists are classified into two groups, positive resists and negative re-
sists. When positive resists are exposed to light they dissolve quickly in
the developers while the unexposed regions of negative resists are easily re-
moved. Once developed the photoresist is washed off, leaving the pattern
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engraved into the base material allowing for complex channel designs, en-
abling multiple tests to run simultaneously across a number of channels on
a single chip. Microfluidic and electronic components can also be integrated
onto a single chip, at a low cost, allowing for the development of dispos-
able chips with integrated sensors. These chips could be used to preform
chemical reactions, and calibration-free analytical measurements with small
quantities of complex samples such as whole blood [28].
Lamination Technologies
Lamination technologies are well suited to planar flow devices, allowing for
rapid development of 3D fluidics at a low cost.
Single Sided PSA
 Double Sided PSA
Adhesive 
Adhesive 
Adhesive 
Roller
Roller
Lamination through pressure
Lamination through temperature
Oven
PSA
PSA
PSA
PSA
Glass
PSA
Lamination of PSA to glass substrate
A B
C
Figure 1.11: Lamination technologies. A) Types of PSA. B) Lamination
through pressure and temperature. C) glass substrate laminated with PSA.
Figure 1.11 shows a cross-section of a thin polymer commonly used
within lamination technologies. When an adhesive material is applied on
one or both sides of the polymer a product known as pressure sensitive ad-
hesive (PSA) is created. Figure 1.11-B shows how PSA can be activated
through either pressure or in some cases temperature; in the figure, two
24
Chapter 1. Introduction
pieces of PSA are being laminated together. Glass (with is biocompati-
bility and optical properties) can be used as a substrate for hybrid chips.
When combined with a channel cut into PSA and laminated a flow device
can be easily manufactured.
Single layer chip
Channel design cut into PSA 1
2
3
Cover
Glass substrate
1
2
3
Channel design cut into PSA 1
2
4
Cover
Glass substrate
1
2
4
Channel design cut into PSA
3
3
Single Layer
Multi-layer 
Multi-layer chip 
Figure 1.12: Technique to allow both single and multi-layer µ scale structures.
Figure 1.12 shows a single layer flow device with a simple channel and
an inlet and outlet. The cover and glass substrate are laminated between
the layer of double sided PSA containing the channel. To create a 3D
structure this pressure sensitive adhesive (PSA) is stacked in layers of a
single thickness or can be combined into layers of different thicknesses. The
technique allows for both single and multi-layer µ-scale structures to be
cut, manufactured and assembled at a low cost. These structures can range
from complex multi-channel designs, which integrate many different flow
characteristics, to straight channels with a single inlet and outlet used in
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parallel plate flow. PSA can also be cut to create 3D moulds, with the
raised area of PSA allowing the channel geometry to be transferred to the
casting material.
Polydimethlysiloxane in Microfluidic Devices
Poly (dimethylsiloxane) (PDMS) is an excellent material for the fabrication
and rapid prototyping of microfluidic devices which incorporate biological
samples. PDMS is nontoxic, has a low curing temperature and allows a
reversible seal to be formed between the material and substrate [55, 56].
This elastomeric polymer has been used across a range of different applica-
tions from standard planar fluidic devices [57], complex devices integrating
microfluidics valves [58] and a number of different pumping techniques de-
scribed by Grover et al. and Dallas et al. [59, 60]. 3D devices can also
be created by laminating thin layers of PDMS atop one another, while a
UV/Ozone cleaning system is used to bind each layer [61]. This type of 3D
microfluidic device was demonstrated by van Midwoud et al. for the in-vitro
assessment of interorgan drug metabolism using both intestinal and liver
slices [62]. When PDMS is placed under a vacuum any gas within the bulk
is evacuated. Once returned to atmosphere gas is slowly reabsorbed into
the PDMS. This ability allows self-powered integrated devices containing a
dead end channel to be created. This technique has been demonstrated with
both an on-chip sequential injection immunoassay [63] and within a chip de-
signed for the analysis of blood samples [64]. These devices do not require
any external connections, tethers, or tubing commonly used with pumping
systems such as a syringe pump. Along with device manufacture, PDMS
can be used in other areas of MEMS development, such as protein pattern-
ing. PDMS is also the preferred material used to create the stamps needed
for microcontact printing (µCP). This method was developed by Kumar
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and Whitesides for the patterned transfer of thiols onto gold surfaces [65].
Basabe-Desmonts and Lopez-Alonso et al. used spots patterned using µCP
for the measurement of platelet function in whole blood [24, 25]. PDMS
is ideally suited for use with BioMEMS devices, with the ability to mould
µ channels from silicon masters to the development of power-free pumps.
The combination of silicon masters and PDMS has opened up the area of
µCP, allowing complex designs or simple arrays of spots to be patterned
reproducibly and at a low cost. While PDMS may not be ideal for large-
scale manufacture of MEMS devices, it is well suited for rapid prototype
development and continues to be used in BioMEMS design.
1.6 Thesis Aims and Objectives
The aim of the project is to develop a device that would allow a clinician to
test a patient’s responsiveness to anti-platelet therapies and as a diagnostic
tool for individuals at risk of suffering a cardiovascular event. Using cur-
rent technologies in the field of microfluidics a prototype device has been
designed to address the challenge of integrating the use of whole blood,
mixing of reagents, delivery of blood, imaging system and the analysis of
the sample. The prototype lab-on-a-chip device should be demonstrated to
show a detectable difference in an individual’s response in both the presence
and absence of an anti-platelet therapy such as Cangrelor.
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Key Objectives
1. To investigate and characterise how channel geometry affects blood
within a biological assay used to detect the effects of anti-platelet
therapies on an individual.
2. To identify and develop new technologies that can be used to de-
sign and build a single-use prototype point-of-care device to test anti-
platelet therapies.
3. To develop new image processing techniques that will allow for the
automated quality control of a printed protein surface.
4. To develop a technique to automate acquisition of results from com-
plex protein arrays used with the prototype device.
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Chapter 2
Theoretical Background
The study of fluid mechanics has allowed the definition of laws that govern
how a fluid acts whether at rest (static), under flow (kinematics), and the
effect of forces on fluid motion (dynamics). In common usage the word fluid
is generally considered only to include liquids while within the area of fluid
mechanics the word has a much broader definition that includes substances
that continually deform (flow) under an applied shear stress including liq-
uids, gases, plasmas and plastic solids. Substances that do not flow under
stress are in turn classed as solid thus giving the technical difference between
a fluid and a solid. Therefore, A solid can resist shear stress by a static de-
formation. A fluid cannot [1]. This definition facilitates the application of
principles of classical continuum mechanics to determine if a substance is a
fluid or solid. By applying Newton’s second law of motion to a body of fluid
Claude-Louis Navier and George Gabriel Stokes developed a set of equations
to describe the motion of a fluid in response to these forces (See Appendix
E). Known as the Navier-Stokes equations, they are particularly useful in
describing a large number of fluid-based phenomena including the studies
of the ocean currents [2], blood flow in the heart [3], and compressible flow
across an aerofoil [4]. When the complexity of many real world problems
38
Chapter 2. Theoretical Background
is added to the second order and non-linear nature of the equations they
become computationally intensive to solve and in many cases only approx-
imate solutions can be obtained. The development of Computational Fluid
Dynamics (CFD) has allowed many different solution strategies to become
available to the desktop user. CFD software packages are available from
both free and commercial sources. When considering the application of
fluid mechanics to MEMS devices, a number of assumptions can be made
to allow for a significant simplification of the governing equations. The
flow in microsystems are predominantly laminar due primarily to the small
length scales of these devices. This allows the removal of the rotational
components of the Navier-Stokes equations and dictates that viscous effects
dominate over inertial effects, thereby also removing gravitational aspects
for many devices. An exact solution for some microfluidic devices can be
obtained by making some further assumptions and in the case of devices
incorporating a whole blood sample the assumption that the blood is New-
tonian fluid can also be made [5]. Although blood is non-Newtonian this
assumption can be justified when considering the shear thinning response
of whole blood as shown in Figure 2.1.
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Figure 2.1: Diagram showing the relationship between apparent viscosity of
normal blood, plasma at various shear rates made [6].
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Figure 2.1 shows that as the shear rate increases. The deformation of the
red cells starts, causing a reduction in the recorded viscosity. The rate of
deformation starts to stabilise at about 10 s−1 and has fully completed at a
shear rate of 50 s−1, after which the viscosity of blood remains constant [7].
For the purposes of this work whole blood can be considered a Newtonian
fluid as platelet response to shear is typically in the range of 50 s−1 to
1000 s−1 [8].
2.1 Fluid Flow Within Channels
Section 3.1 introduces the concept of degas-driven flow. A degas-driven
channel flow can be approximated as steady flow between parallel plates.
However, the flow rate within the channel of a degas-driven device is nonlin-
ear. A model that accounts for the diffusivity of air in Polydimethylsiloxane
(PDMS) is also detailed in this section.
Chapter 5 introduces a sealed device that uses a rocking-table to create
flow within the channel. The flow rate within these channels can be ap-
proximated by treating it as flow down an inclined plane. The theoretical
background for these conditions has also been detailed within this section.
2.1.1 Steady Flow Between Parallel Plates
P Pz
y
x
0
x
a
L
u
Figure 2.2: Flow between parallel plates.
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Consider a fluid of viscosity µ, flowing between two fixed, infinitely wide
parallel plates of length L, separated by a distance a as shown in Figure
2.2. Assuming the flow is steady (all partial derivatives with respect to
time are zero), parallel (the xy-component of velocity u is zero everywhere),
fully developed and laminar, and there is a constant pressure drop along the
length L the Navier-Stokes equations can be simplified, with a full derivation
included in Appendix C. Under these conditions the flow can be considered
one dimensional, with the velocity u constant along the z direction. When
these conditions are applied Navier-Stokes equations can be reduced to yield
the equation for flow between stationary horizontal plates shown in Eq. 5.1,
where Q is the fluid flow rate, p is the pressure, a and b are channel height
and width, and µ is the fluid viscosity [9].
Q =
a3b
12µ
dp
dx
(2.1)
Shear Rate
Shear rate is an important parameter to be considered when blood is flown
between parallel plates. The adhesion of platelets can be dependent on both
a minimum and maximum shear rate. To calculate the wall shear force, τw,
we use the shear force equation.
τw = µ
∣∣∣∣dudz
∣∣∣∣
z=0,z=a
=
a
2
dp
dx
(2.2)
For practical analysis, Eq. 2.1 and Eq. 2.2 can be combined to give
τw =
6µQ
a2b
(2.3)
which allows the calculation of wall shear force in terms of chamber dimen-
sions, fluid viscosity and volume flow rate.
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Aspect Ratio
Eq. 5.1 shows the approximate expression for the flow rate in flat rectangular
channels. This is a highly aspect-ratio-dependent approximation of volume
flow rate and breaks down as the aspect ratio approaches 1. In the case of
an aspect ratio of one third, a = w/3, the error is as much as 23%, where
a is the channel height and w is the width. This error falls to 7% for an
aspect ratio of one tenth, a = w/10 [10]. During the design of microfluidic
channels the aspect ratio needs to be grater then one tenth for an error less
than 7%.
1:1 Ratio
1:4 Ratio
1:8 Ratio
Velocity Profile 
Figure 2.3: Velocity profiles through rectangular ducts of varying aspect ratios.
Figure 2.3 shows channels with an aspect ratio of 1:1, 1:4 and 1:8, with
the velocity profile highlighted for each. Comparing the velocity profile
between channels of increasing aspect ratio (1:1 to 1:8) the impact upon
the profile as a result of the vertical wall is decreased, thereby allowing
for the flow to be assumed as one dimensional. This simplification in the
governing equations also allows for the flow rate, and therefore the shear
rate, to be considered constant across most of the channel width.
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2.1.2 Degas-Driven Flow Model
The same equations derive for flow between parallel plates can be used for
flow within a degas-driven flow (DDF) channel. The flow rate within a DDF
channel decreases over time, while flow within a parallel plate flow device
remains constant. The channel designs developed within Chapters 3 and 5
utilise DDF and therefore a model used to approximate the change in flow
rate with respect to time is derived.
DDF allows for passive pumping along a dead-end channel and is detailed
within Section 3.1. DDF does not require any tubing, additional equipment
or power source typically used with other pumping methods. DDF utilises
both the gas solubility and permeability properties of PDMS to transport
a fluid along a channel length. The channel is moulded within the PDMS
block and has only one inlet, created by punching a hole into one end of the
channel, to create a dead end channel.
A degas-driven flow model has been proposed by Liang et. al. to describe
the air flux from the micro channel into the PDMS bulk [11], denoted in the
Eq. 2.4 as Fluxair. The model takes advantage of the equation described
by Hosokawa et. al. [12] and was adapted with the addition of a scaling
factor (Catm), required to account for the difference in the geometries of the
two systems. Eq. 2.4 was derived from Fick’s laws of diffusion assuming a
1-D system and concentration of air (CPDMS) inside the PDMS of zero after
degassing and before the experiments. Where the air concentration in the
atmosphere is Catm, DPDMS is the diffusivity of air in PDMS, LPDMS the
thickness of PDMS, and tidle represents the post-vacuum idle time before
loading the liquid into the channel.
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Figure 2.4: Permeability of PDMS slab. Two views of a channel inside a
PDMS slab are shown to demonstrate the diffusion of air into the material. The
important values used to calculate the flux are also labelled.
Fluxair = K22DPDMS
(
Catm − CPDMS
LPDMS
)
exp
(−pi2DPDMS(t+ tidle)
4L2PDMS
)
(2.4)
The model assumes Poiseuille flow within a square channel where L, W
and H describe the length, width and height, respectively. When calculating
the fluidic resistance (Rfluidic) a scaling factor was required to account for
complex factors such as surface tension and the hydrophobicity of PDMS.
The fluidic resistance is described in Eq. 2.5, where µ is the fluid viscosity
and can be used to determine the volumetric flow rate Q (Eq. 2.6).
Rfluidic =
12µL(W +H)2
(WH)3(1 + 5H
6W
)
(2.5)
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Q =
dP
Rfluidic
(2.6)
Assuming the air acts as an ideal gas, the pressure difference can be
equated to Patm, the amount of air inside the channel (nchannel) and the
fluid-free, gas-filled volume (Vfree). The ideal gas law is shown in Eq. 2.7
where P is pressure, R is gas constant, T is temperature, mass (m) and the
molar mass (M) (in grams per mole):
Ideal gas law:
n =
m
M
PV = nRT (2.7)
Therefore, the pressure difference for the modelled channel can be derived
as:
dP = Patm − nchannelRT
Vfree
(2.8)
Where Patm is atmospheric pressure.
nchannel can be related to the flux of air using the relationship:
nchannel = ninitial −
t∫
0
FlexairAfreedt (2.9)
Where ninitial is the total air inside the channel at t = 0 and Afree is the
available surface area exposed to air. Therefore, the free volume Vfree and
free area Afree can be given by:
By substituting Eq. (2.5) and (2.8) into Eq. (2.6) Q can be expressed in
terms of:
Q = K1
(WH)3(1 + 5H
6W
)
12ηL(W +H)2
(
Patm − nchannelRT
Vfree
)
(2.10)
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By substituting Eq. (2.4) into Eq. (2.9) nchannel can now be expressed in
terms of:
nchannel =
PatmWHL
RT
−K22DPDMS
(
Catm − CPDMS
LPDMS
)
exp
(−pi2DPDMS(t+ tidle)
4L2PDMS
)
Afreedt (2.11)
Applying the boundary conditions for t = 0;
DAfree
dt
= −2(W +H)
WH
Q (2.12)
dVfree0
dt
= Q (2.13)
nchannel
dt
= −K22DPDMS
(
Catm − CPDMS
LPDMS
)
exp
(−pi2DPDMS(t+ tidle)
4L2PDMS
)
Afree
(2.14)
Therefore, the free area and volume at t = 0 is
Afree0 = 2L(W +H) + Aend (2.15)
Vfree0 = WHL (2.16)
nchannel =
PatmWHL
RT
(2.17)
Resulting in the following:
dQ
dt
= −K1
(
(WH)3(1 + 5H
6W
)
12ηL(W +H)2
)
RT
[(
1
Vfree
)
dnchannel
dt
−
(
n
V 2free
)
dvfree
dt
]
(2.18)
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dQ
dt
= −K1
(
(WH)3(1 + 5H
6W
)
12ηL(W +H)2
)
RT
[(
n
V 2free
)
Q−
(
1
Vfree
)
(
K22DPDMS
(
Catm − CPDMS
LPDMS
)
exp
(−pi2DPDMS(t+ tidle)
4L2PDMS
)
Afree
)]
(2.19)
While Liang et. al. (2011) reported a good correlation between ex-
perimental and modelled volumetric flow rates (Q) the values used for K1
and K2 need to be determined experimentally and may not take into ac-
count complex channel geometries like those detailed in Chapter 4. As such,
this model is of limited value and in many cases an experimental approach
should be taken when designing such devices.
2.1.3 Rocking Table
The iPA assay uses a rocking table to allow the blood to flow across the
protein spots. The height of the blood changes as the rocker moves from
side to side. This section details two methods for calculating this height.
Software was also developed to help characterise the moving of the rocking
table as is detailed in Appendix E.
Software
θ
hf
h0
hf
θ
Area of interest 
A B
Figure 2.5: A) Channel at zero degrees (h = h0). B) Channel at θ therefore
h = hf
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Software allows for the changes in angle of the rocking table to be
recorded over time. As the slow moving rocking table oscillates the height h
will change across the area of interest, located half way along the channels
length. Figure 2.5 shows the rocking table at 00 and inclined at an angle θ.
The interface between the fluid and air remains horizontal despite the angle
of tilt causing the fluid height to change as the table moves. The following
equations used to calculate the fluid height assume the table movement is
sinusoidal and at a constant speed.
θ = θmaxsin
2pit
T
(2.20)
hf = h0 + (L/2− x)tanθ θ ≤ θ0 (2.21)
hf =
√
2h0Ltanθ − xtanθ θ ≥ θ0 (2.22)
For a rocking angle θ ,assuming a sinusoidal function, at time t with a
maximum table angle of θmax for a time period of T , hf should be used in
Eq. 2.27 when calculating the flow rate.
Flow Down an Inclined Plane
In many microfluidic devices the fluid is transported through a channel
completely bound by both the upper and lower boundary, as detailed in
Section 2.1.1. Flow within a rocking table can be approximated as flow down
an inclined plain when calculating the height of the fluid. The equation
that governs such flow can be derived from the Navier-Stokes equations
by making the same simplifications used for flow between parallel plates,
thereby yielding.
∂2u
∂z2
=
1
µ
∂p
∂x
(2.23)
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where x and z are coordinates along and normal to the plate, u is the
velocity components in z, p is pressure and µ is the viscosity of the fluid.
h
a
z
x
Figure 2.6: Viscous flow down an inclined plane.
Figure 2.6 shows fluid flowing down a inclined plane at an angle α where
x distance along the plane where z is the transverse coordinate so the surface
of the plane corresponds to z = 0 and the fluid forms a uniform layer of
depth h over the surface. g is the acceleration due to gravity. In this case,
there is no gradient in the actual pressure in the x-direction, and the flow
down the plane is driven entirely by gravity.
Therefore, for fluid flowing down a inclined plane we can write.
∂2u
∂z2
= −ρ g sinα
µ
(2.24)
Where, ρ is the density of the fluid.
The application of the no slip condition at the surface of the plane,
z = 0, yields the boundary condition u = 0. A second boundary condition
can be determined by assuming that the finite inertia and viscosity of air are
both negligible at the fluid/air interface, z = h. The normal viscous stress
σxz can be let equal zero (σxz|z=h = 0) by assuming there is nothing above
this interface that can exchange momentum with the fluid. This allows the
following boundary conditions to be applied.
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u = 0 @ z = 0
du
dz
= 0 @ z = h
(2.25)
applying these boundary conditions yields
u =
ρ g sinα
2µ
z (2h− z). (2.26)
The profile remains parabolic and is the same as the lower half of the
profile obtained when fluid flows between parallel plates at a distance 2h
apart (Figure 2.6).
The flow rate Q through a section of with a width w, where b is the unit
width, and height h can be approximated by [13, 14]
Q =
∫ h
0
u dz =
ρg sinαh 3
3µ
(2.27)
For a given flow rate (Q) the depth of the layer covering the plane
becomes.
h =
(
3µQ
ρg sinα
)1/3
. (2.28)
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Chapter 3
Characterisation Of
Degas-Driven Flow
Advances in microfluidic technologies have allowed for the development of
new, low-cost point-of-care devices (POC). These devices offer a number of
advantages including automation of manual steps, improvements in assay
accuracy, reduced reagent costs, minimising sample volumes and a decrease
in the overall analysis time [1, 2]. Microfluidic platforms enable the study
of single cells and cell populations by accurately controlling fluid dynamics
(e.g. shear rate), effectively handling small fluid volumes, localised com-
pound delivery and facilitating the imaging and analysis for both real time
and stationery applications [3]. POC devices can allow for current complex
laboratory assays to be simplified, thereby giving access to testing in ar-
eas of the world where traveling to a clinic or the storage and delivery of
a sample may be impossible [4, 5]. Current shear-dependent platelet func-
tion tests, such as the Analyzer-100 (PFA-100), Impact-R cone & plate(let),
and VerifyNow, require mL sample volumes and/or complex cartridges or
electronics [6, 7]. When designing a flow-based device, where shear rate is
required or may have a detrimental effect on assay performance, it is critical
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to control and understand both the shear rate and flow rate achieved within
the device.
Self-pumped devices do not rely on large equipment such as syringe
pumps. These pumps are traditionally used in research or clinical labora-
tories and render many microfluidic techniques ill-suited for use as POC
devices. Self-powered microfluidic devices were previously reported using
technologies such as gravity-driven [8], evaporation [9] and droplet based
passive flow [10]. The requirement for gravity-driven devices to be primed
before use and the associated difficulty in achieving reproducible flow (un-
der normal clinic conditions) for both evaporation and droplet based passive
flow, show these technologies still have a number of disadvantages, which
may render them unsuitable for use as low-cost POC devices. Degas-Driven
Flow (DDF) is a power-free method of flow propulsion more suited to point-
of-care devices, proposed by Hosokawa et al. DDF allows for power-free
pumping of fluid within a dead-end channel [11]. The characterisation of
a 50 µm × 50 µm degas-driven device was demonstrated by Liang et al.
The device showed reproducible flow after being placed under vacuum (de-
gased) for 45min. The device was still capable of stable flow after being left
idle for 7min [12]. The device was able to obtain a maximum flow velocity
ranging from 0.2 to 3 nL/s and the area of exposed polydimethylsiloxane
(PDMS) was found to have negligible effects on the fluid flow [12]. Self-
pumped integrated DDF devices have also been demonstrated with both an
on-chip sequential injection immunoassay [13] and an integrated microflu-
idic blood analysis system [14]. These devices do not require any external
connections, tethers, or tubing and work with serum and whole-blood, re-
spectively. However, for shear dependent assays, such as platelet function
testing, a flow rate within microliters per second (µL/s) range is required
for a channel geometry with an aspect ratio greater than 1/10, as shown
in Section 2.1.1. The channel is also required to store the sample once it
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has passed over the test area, unlike flow chambers where a syringe can be
used to store the sample. Many shear dependent assays require the shear
rate to stay within a defined maximum and minimum range. This creates a
unique set of challenges when designing DDF devices, where the flow rate,
and therefore the shear rate, will decline as the fluid fills the channel.
This chapter introduces a new low cost manufacturing method for the
rapid development of DDF devices and a novel software package that al-
lows the calculation of flow rate within complex channel geometries. This
manufacturing method was used to develop and characterise a self-powered
disposable microfluidic DDF chip. The chips were designed to better under-
stand how the flow rate, and thus the shear rate, could be controlled over
time. To better understand the capabilities of DDF flow and how chan-
nel geometry could be utilized, a number of different channel geometries of
varying widths and lengths were characterised.
3.1 Principles Of Degas Driven Flow
Degas-driven flow utilises both the gas solubility and permeability proper-
ties of PDMS to transport a fluid along a channel length. The channel is
moulded within the PDMS slab and has only one inlet, created by punch-
ing a hole into one end of the channel. Polydimethylsiloxane (PDMS) is
an excellent material for the fabrication and rapid prototyping of microflu-
idic devices which incorporate biological samples. It is nontoxic, has a low
curing temperature and allows a reversible seal to be formed between the
PDMS and substrate. When PDMS is placed under a vacuum any gas
within the bulk is evacuated. Once returned to atmosphere gas is slowly
reabsorbed into the PDMS. Figure 3.1-A shows how the reabsorption of air
can be used to create fluid flow within a dead end channel. This technique
is referred to as degas-driven flow (DDF). The PDMS and substrate are
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Figure 3.1: Principle and of degas-driven flow device. A) Assembly of DDF
device using PDMS slab and poly(cycloolefin) (COP) sheet. B) Principle of DDF
flow shown in a single length channel. i) Diagram of a section of the channel with
a total length (L) as the fluid enters and the air starts to degas at t = 0. ii)
Diagram of a section of the channel after the flow has moved a length dx along
the total length (L) thereby reducing the available channel by x− dx.
assembled before the DDF device is placed into a vacuum and degased for
a predefined time; this allows any air (and water vapour) molecules within
the PDMS bulk to be evacuated. As soon as the device is removed from
the vacuum, the open channel will refill immediately while the PDMS bulk
will slowly start to reabsorb air back through both its external faces and
the channel walls (Figure 3.1-B). A difference between atmospheric pressure
and the pressure within the channel is created once the sample is loaded
into the inlet, thereby closing off the channel, allowing no new air to en-
ter the channel and replace that absorbed through the channel walls. It is
this pressure difference that causes the fluid to flow along the channel and
will only stop when the PDMS becomes saturated with air or the pressure
difference can no longer overcome the surface energy. Figure 3.1-B shows
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a simple channel within the assembled chip. The sample has been loaded
and the fluid is moving along the channels length (L). Two sections of the
channel have been magnified to show the fluid at time t = n and t = n+ 1.
The fluid moves a length dx between these time points. The flow rate de-
creases over time as the available pumping area (area of exposed PDMS)
decreases by a length x− dx, where x is the length of the unfilled channel.
The available pumping area for time t within the dead-end DDF channel
is calculated from the channel height a, width b and length x, and only
includes the two side-walls, roof and channel-end.
3.2 Manufacture of PDMS Chip
Photolithography is the traditional method used for microchannel fabrica-
tion. Photolithography typically requires relatively expensive equipment, a
mask to be manufactured, photoresist and in some cases a cleanroom. In
contrast the cost and ease of creating or modifying a design using a pressure
sensitive adhesive (PSA) allows for rapid prototyping from the lab bench
using a PSA cutter. Pressure sensitive adhesive is used in applications
from automotive interior trim assembly to transdermal drug patches, with
the former designed for permanent adhesion and the latter when reversible
adhesion is required.
To manufacture the device channel, designs were created using the Au-
todesk AutoCAD 2012 software and saved in the AutoCAD DXF (Drawing
Exchange Format) CAD data file format which enables data interoperabil-
ity between AutoCAD and other programs. The channels were cut into a
single-sided PSA sheet of 50 µm or 80 µm thickness. Figure 3.2-A shows
the PSA being first placed onto a reusable backing sheet before the start
point of the cutter is selected. A number of test cuts are made to allow the
operator to set the depth of the blade; once cut, the design is removed from
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Figure 3.2: Preparation of PSA mould for manufacture of PDMS Chip. A)
The location of the GraphTec cutter blade and housing are shown along with the
backing sheet. B) Shows the four steps required to remove the channel from the
waste PSA and roll it onto the surface of a petri dish.
the backing sheet. Figure 3.2-B illustrates how the channel is rolled onto
the surface of a clean petro dish. The dish can be placed in the oven at 700
for 30 minutes to remove any air trapped beneath the adhesive.
A 10:1 mix of PDMS and curing agent is mixed and poured into the
mould covering the channels completely. The channel designs are placed at
the centre of each dish to ensure an even depth of PDMS and to reduce any
possible damage to the channels when the PDMS is removed with the aid
of a scalpel. The bubbles that were introduced into the PDMS as it was
mixed are removed by placing the dish under vacuum for 1 hour 30 minutes
or until no bubbles are visible, before curing for 60 minutes at 70o. The
now cured block of PDMS must be allowed to cool before it is ready to be
removed from the dish. As the mould is reusable care is taken to ensure the
surface of the dish is not scratched upon lift-off of the PDMS slab. Each
channel within the block is cut into individual chips and an inlet punched
at the start of the channel, taking care to remove any PDMS flakes that
may affect how the chip bonds to the substrate. When the chip is placed
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onto the substrate, a reversible bond creates the sealed channel with a single
inlet required for degas-driven flow.
Finish of Channel Edge
PSA Channel PDMS Channel
A B
PSA Mould  
25
0 
μm
Figure 3.3: Microscope Images (20x magnification) of (A) PSA the mould
alongside an image of (B) the channel in PDMS chip created from the mould.
Figure 3.3 shows the finish achieved at the edge of the PSA channel and
the edge of the channel when cast in PDMS. The PSA image shows small
inconsistencies along the channel edge as the blade cuts the PSA. When
this is compared to the channel cast in PDMS, these inconsistencies are
still visible alongside a number of bubbles which were not removed when
the mix was placed under vacuum. Although a better defined channel edge
can be achieved when using photolithography, the finish achieved using a
PSA mould should be acceptable. Given that the channels have a low as-
pect ratio and only the centre will act as an assay area, the overall finish
will be suitable for prototype channel development. However, as this manu-
facturing technique had not yet been characterised, software was developed
to detect flow rates. By comparing flow rates across different moulds and
channel geometries, it was possible to determine if the flow was reproducible.
3.3 Flow Rate Detection Software
Within this thesis two distinct image processing techniques were developed
for the analysis of fluid flow. The first allows for the analysis of simple
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channel geometries, while the second can analyse complex channel geome-
tries with multiple directions of fluid flow. The software was developed to
replace a manual system that required the user to record the time at which
the fluid passed from one square of a grid to the next; with the area of
each square known the flow rate could be calculated. This technique was
time-consuming, required the user to observe the flow for the full run time
and limited the number of data points to the density of the grid. By au-
tomating this process inter-user variability for flow rate calculations could
be removed along with the need to observe the flow, freeing the operator
to complete other tasks. Both techniques used a webcam positioned above
the chip, and were available within a single software package developed in
C++ as part of this thesis.
t=n t=n+1
Difference in fluid length
Image From Camera
(i) (ii)
(i) - (ii)
Image From Camera
dt
dt = (n+1) -n 
Figure 3.4: Calculation of flow rate using acquired images
Figure 3.4 show two images at t = n and t = n + 1. These images
were acquired from the camera, before being processed to determine the
length the fluid had travelled between t = n and t = n + 1. This length
can be used to calculate the velocity of the fluid during the time dt. Given
that the channel is of known width and height the velocity can in turn be
used to calculate the volumetric flow rate (Q). The processing steps and
calculations required are detailed in Appendix D
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3.3.1 Analyses of Complex Channel Geometries
The simple allowed for the analyses of simple rectangular channels. De-
gas devices can also contain channels that can vary in width along their
length, contain bifurcations, corners, curves or other complex features. Non-
rectangular channels therefore required a new flow rate detection technique
to be developed. As multiple channel designs required characterisation it
was important that the new technique was robust, flexible, automated and
easy to use. A novel flow detection method was developed to calculate the
flow rate in complex channels. Complex channel flow detection (CCFD)
reads in the DXF file that stores all the point data needed to build an
outline of the drawing it contains. A channel design was drawn using Au-
toCAD, this DXF file was readily available.
Figure 3.5-1 shows the image as it is acquired from the camera. The
image is processed (Figure 3.5-2), before a stencil is applied to create a
series of images used to calculate the flow rate. The channel DXF file is
used to create a stencil which is placed over the channel within the image.
Figure 3.5-4 shows a stencil applied at a number of different time point t=n
to t=n+4. The regions extracted from the input images are of the same size
as the stencil, with any non-zero value considered fluid as only areas inside
the polygon (channel) are included. This makes it possible to calculate the
area (m2) of the filled channel, for each of the regions extracted, and by
multiplying the area by the channel height (50 µm) the total volume of
fluid within the channel can be determine for all time points.
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Each image is time stamped allowing for both the time and difference in
volume between n and n+1 to easily be determined, in turn allowing for the
volumetric flow rate (Q) for each time point to be recorded. The methods
used to create the stencil and filters used to detect the flow rate for complex
channels are detailed in Appendix D.
 Image From Camera
Image Masked
Image after DXF filter is applied
DXF stencil 1
2
3
4
t=n
t=n+1
t=n+2
t=n+3
t=n+4
Figure 3.5: Screen shot of software used to calculate flow rates for a complex
channel using a DXF file. 1-2) The imported DXF file is shown in a yellow box,
the box is placed over the image before a threshold is applied. 3) The DXF stencil
is applied to the threshold image which sets any pixel outside of the channel to
0 (black) and at the same time crops the image to the stencil size. 4) Image of
the stencil and a series of cropped images showing how only the area within the
channel is extracted from each image.
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Figure 3.6: Simple and complex flow rate detection methods compared.
Figure 3.6 shows the complex method compared well to the manual
method when a channel of 120 mm in length was used to make the com-
parison. As the user records the distance the fluid has travelled along a
channel, this value was plotted within the graph for both methods. The
manual method is quicker to set-up, as no stencil is required, but is lim-
ited to only straight channels. While the complex method can process both
straight and complex channels it required more set-up before any result
can be calculated. Both methods required the user to know the width and
height of the channel before a flow rate can be calculated.
3.3.2 Summary
This section introduced both a new manufacturing and flow detection method,
for use with degas-driven flow devices. By using these techniques together,
prototype DDF chip(s) could be designed and characterised at a low cost
and in a short time frame. However, the chips manufactured using this new
method had not yet been characterised. Therefore, a series of channels of
varying width and length were tested with water.
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3.4 Characterisation of DDF Flow
The characterised channel designs were cut into a pressure sensitive adhesive
before being rolled onto the surface of a petri dish. Depending on the
channel geometry a different size petri dish is required and should allow for
a suitable area of Polydimethylsiloxane (PDMS) surrounding the channel,
thereby allowing the PDMS to create an air tight seal with the substrate.
Figure 3.7 illustrates how the dish is filled with a mixture of PDMS and
curing agent, before being heated and allowed to cure. Once cured, the slab
can be removed from the dish and cut to size before the inlet is punched
into one end of the channel. For each channel characterised, the volume of
PDMS used results in a slab of the same height.
Cut  Lines
Punched inlet
PDMS Slab
PDMS
MIX
PDMS
Curing
agent
Mixer 70oC Oven
Figure 3.7: PDMS Mixing. The PDMS is first mixed (10:1) before it can be
poured into the mould and heated at 70oC for 60 min. Once cured, the slab can
now be removed and cut to size.
In order to determine the flow rate of fluid through the channel, software
was developed to acquire images from a camera and carry out the required
post processing. The software outputs the fluid velocity, flow rate and shear
rate and was used to acquire all data within this chapter.
τ = Q
(
6µ
a2b
)
(3.1)
Eq. 3.1 shows that shear rate (τ) can be calculated from the channel height
(a), width (b), viscosity (µ) and volumetric flow rate (Q). Only changes in
Q will affect the shear rate as a, b, and µ are constant for a given chan-
nel. However, the flow rate within DDF channels is affected by the area
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of exposed PDMS which will change if channel geometry is altered. The
height (a) of the pressure sensitive adhesive (PSA) used to create the DDF
channel is fixed at 50 µm, allowing only the width (b) and channel length
to be modified. If the width is changed when calculating the shear rate
using Eq. 3.1, both the volumetric flow rate (Q) and channel width (b) will
have an effect on the resulting shear rate. Therefore, to control the shear
rate, the effect channel geometry has on the volumetric flow rate (Q) must
first be understood. This was achieved by comparing channels of increasing
width, with channels of constant width but with an increased length.
Table 3.1 shows the 13 channels used to characterise the flow rate, di-
vided into two sets of 6 with 1 channel common to each set. For example,
as the width of channel 1 was increased the length of channel 8 (of fixed
width) was also increased, so the area of exposed PDMS would approxi-
mately match. For each channel, the average area of exposed PDMS was
calculated by multiplying the length (L) by the width (b) by height (a) and
the total footprint for each device was calculated by multiplying the length
(L) by width (b). The analysis was simplified by assuming that the foot-
print area was equal to the area of exposed PDMS as the difference between
the average area and total footprint was less than 6% (Table 3.1).
Flow Characteristics
Unlike many flow chamber devices, degas-driven chips do not have a syringe
to store the fluid once it has passed over the assay area. This makes the
ability to store the blood an important design consideration. It is also
advantageous to ensure the test area is clear of blood, while allowing the
required volume to pass through the channel for the assay to work. A clear
assay area also allows efficient imaging of the surface of the chip. As can
be seen in Figure 3.8-A, approximately 70% of the channel volume was
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Set 1 Set 2 Average
Channel 1-4 mm Channel 20-80 mm Area Of Foot
In Width In Length Exposed Print
1-4 mm In Width 20-80 mm In Length PDMS (mm2) (mm2)
1 8 53.5 50
2 9 79 75
3 10 104.5 100
4 130 125
5 11 155.5 150
6 12 181 175
7 13 206.5 200
Table 3.1: List of 13 different geometries characterised. Split into two sets of
corresponding footprint areas Set 1 contains channels changing in width from 1 to
4 mm in increments of 0.5 mm while Set 2 contains channels changing in length
from 20 to 80 mm in increments of 10 mm. Channel 4 is included in both Sets
1 and 2. The average area of exposed PDMS (AAEP) is also listed alongside the
foot print area (FPA) for each set of corresponding channels. AAEP includes all
surfaces within the channel, while FPA only includes the top surface and not the
side walls of the channel.
filled with fluid after 7min for all the channels listed in Table 3.1 with no
significant difference across all geometries tested.
A typical flow rate profile for a 2.5 by 50 mm channel is shown in Fig-
ure 3.8-B, where a rapid increase in flow rate was observed for the first 100
seconds after the fluid was introduced into the channel (stage 1). After
approximately 100 s or 10 % of the total time recorded the flow rate then
progressively decreases from its maximum (stage 2), before gradually de-
creasing to a stop (stage 3). This result shows that flow rate within DDF
channels is non-linear over time and therefore there is no average flow rate
for a given channel. As shear rate plays an important role in platelet de-
pendent assays, controlling the maximum and minimum flow rate, and thus
the shear rate, is a key goal when designing new devices. For many shear
dependent assays there is typically a range over which the sample can flow.
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Figure 3.8: A) Percentage of channel filled after 1000s for both sets 1 and 2.
B) Example of the flow rate profile for the first 1000s of flow in a DDF device
split into three stages.
Effects of Channel Geometry on Flow Rate
The effects of geometry on flow rate were investigated for the channels set
out in Table 3.1. The channels are split into two sets set 1 (variation in
width) and set 2 (change in length). Channel IDs 1, 2, 3, 4, 5, 6 and
7 make up set 1 while channels with the ids 8, 9, 10, 4, 11, 12 and 13
make up set 2. To determine if reproducible flow could be achieved and
the shear rate controlled between an upper and lower limit seven chips were
tested for each channel design. Figure 3.9 shows the results of these tests.
Figure 3.9-A details the maximum flow rate (maximum range) recorded for
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each channel. The columns had been grouped by footprint area in order to
highlight the effect channel geometry has on flow rate, when compared to a
channel of equivalent footprint area. Figure 3.9-B shows the flow rate after
500 seconds, thereby representing the minimum range for an assay time of
500 seconds. This time point was selected as it matched the maximum time
many flow based platelet assays are run.
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Figure 3.9: Comparison between devices with equivalent footprint areas. The
maximum flow rate across different footprints (A), the flow rate after 500 seconds
(B) were plotted. Set 1 includes channels of widths 1 mm to 4 mm while Set 2
includes channels 20 mm to 80 mm. As a channel id 4 is included in both sets
of data only one column is shown. Each figure has an n=7.
As expected, increasing the area of exposed PDMS (pumping area) re-
sults in a corresponding increase in flow rate. This can be explained by
equating the pressure difference created by DDF with that of a pump. In-
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creasing the available pumping area affects how fast air can be removed from
the channel resulting in a greater pressure difference, thereby increasing the
flow rate within the DDF channel. This principle is shown in Figure 3.9
where a larger footprint area gave the greater flow rate, with the flow rate
increasing as the area of exposed PDMS was increased across the 13 chan-
nel designs. The figure shows (A) the maximum recorded flow rate for each
channel and (B) the flow rate after 500 seconds. No statistical difference
in the flow rate across footprint areas of 75 mm2 or greater, within both
graphs. In contrast, variances were observed in areas 75 mm2 and less, pos-
sibly as a result of the time taken to achieve gradual flow in shorter channel
lengths. The data indicates that changes to the channel width do not af-
fect the flow rate for equivalent footprint areas and a reproducible flow rate
can be achieved. The results indicate the new manufacturing technique is
suitable for use when designing prototype degas-driven chips.
Effects of Channel Geometry on Shear Rate
Shear rate (τ) plays a key role in how platelets function, platelets respond
differently over a range of shear rates. It is therefore important to control
shear rate within the channel of any prototype device, τ was calculated
using Eq. 3.1. When calculating the tau for two channels, with fluid passing
through them at an equivalent flow rate (Q), the cross sectional area of a
channel has direct effect on the value of the shear rate calculated. As the
height of the channels tested is fixed at 50 µm, only the width (b) will
result in a change to the shear rate. Figure 3.9-A showed no significant
effect on the maximum flow rate for channels with an equivalent footprint
area. However, the channel width (b) was increased from 1 to 4 mm for those
channels within Set 1. This change in width will therefore have an effect
on the resulting shear rate, when compared to the channels of equivalent
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footprint area within Set 2. This difference has been plotted in Figure 3.10
and shows how the maximum shear rate can be controlled by changing the
geometry of the channel.
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Figure 3.10: The maximum shear rate for the two sets is shown. The max shear
rates increase with the increase in length while the shear rate remains constant
when the width is increased from 1 to 4 mm.
As the length of the channel was increased the shear rate appreciably
increases from 3.8s−1 to 19.2s−1. In contrast the shear rate for channels
of increasing width alters marginally from 10.5s−1 to 14.4s−1. As expected
when the channel geometry remains constant the shear rate increased and
as the channels width is incremented the shear rate is affected. These results
indicate the importance of channel geometry in shear dependent DDF device
design and the adaptability of DDF devices for controlling shear rate. For
a device requiring a high flow rate and low shear rate an increase in channel
width would give the best result, while an increase in the channel length
would result in both a high flow and shear rate.
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3.4.1 Discussion and Conclusion
When designing devices for shear dependent assays the required shear rate
can be maintained through a powered pumping system. While these systems
have been in use for some time and are well characterised, size, cost and
requirement for tubing make them unsuitable for some point-of-care devices.
This chapter introduced a low cost manufacturing technique allowing for the
rapid prototyping of degas-driven (self-powered) devices. The experimental
results show reproducible flow conditions can be achieved using degas-driven
devices, manufactured from pressure sensitive adhesive moulds, allowing for
a prototype device to be designed and manufactured at lower cost than
traditional methods such as photolithography.
In order to make comparisons the channels listed in Table 3.1 were
grouped by footprint area, 6 groups of 2 channels were created. The re-
sults clearly showed, a corresponding rise in flow rate through the channel
as the area of exposed PDMS was increased. No significant difference in flow
rate was observed between channel designs within each of the 6 groups. This
finding allows for the design of devices with the ability to control both the
flow and shear rate for a defined assay time. Shear is an important design
consideration for the development of devices where its control directly af-
fects assay results, such as anti-platelet therapies. The characterisation of
flow detailed within this chapter indicates that DDF prototype devices of-
fer great potential for further development and integration of assays where
controlling shear rate is a requirement.
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Chapter 4
Degas-Driven Device Design
The control of shear stress is both a challenge and key goal when developing
a new point-of-care platelet function test, as the actuation of fluid flow in a
chip with reliable shear rate must be achieved using inexpensive and com-
pact instrumentation [1]. DDF devices are inexpensive and self-powered
and do not require an external pump or tubing, making them ideal for use
as a point-of-care device. Such a device is presented in this chapter and in-
tegrates the Individual Platelet Adhesion (iPA) assay onto a self-actuating
microfluidic chip for monitoring platelet adhesion on 6 µm diameter fibrino-
gen spots. Alterations to geometry of the device to achieve shear rates in
the range of 20− 120 s−1 are also documented. Finally the capacity of the
device to quantify the effects on the P2Y12 platelet receptor when clopido-
grel is added in-vitro to blood, showing device potential as a point-of-care
device for monitoring the effect of anti-platelet therapy in whole blood.
4.1 DDF Shear Results in Whole Blood
An important consideration when designing degas-driven chips is whether
the flow rate will fall below the required minimum within the assay time for
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a given shear rate. The results from Figure 3.10 shows a maximum shear
rate of 20 s−1 can be achieved, with the channels listed in Table 3.1 . When
considering assays that require fluid volumes in the µL range and a shear
rate in excess of 20 s−1 a single channel becomes impractical, as the required
channel length would be difficult to manufacture and degas.
120mm channel equivalent to 2leg chip
160mm channel equivalent to 3leg chip
Flow
Flow
2 Leg Chip 3 Leg Chip 4 Leg Chip
Flow
Flow
Flow
1 2 3
4
5
Figure 4.1: A semantic of three devices device designed to compare the shear
rate in both water and blood. n = 4
Due to the limited size of the desiccator it was not possible to manufac-
ture channels greater than 160 mm in length. This limitation was overcome
by splitting the channel and placing these interconnected channels side by
side. Figure 4.1 shows channels of 120 mm and 160 mm in length, along-
side an equivalent length channel containing the interconnected channels
referred to in the figure as legs. Three designs were created with 2, 3 and 4
legs, respectively. The shear rate in water for the 2 leg design (36 ± 2.1 s−1)
was equivalent to that of the 120 mm single length channel (38 ± 1.21 s−1).
When the 3 leg channel (47 ± 1.8 s−1) was compared to the 160 mm single
channel (46 ± 1.81 s−1 the same trend was observed. This result indicates
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the legs had no effect on the shear rate obtained.
Water
S
he
ar
 R
at
e 
(s
-1
) 
60
50
40
30
20
10
70
2 Leg 3 Leg 4 Leg
Blood
S
he
ar
 R
at
e 
(s
-1
)
60
50
40
30
20
10
70
2 Leg 3 Leg 4 Leg
A B
Figure 4.2: A) Shear rate observed in devices containing 2,3 and 4 legs after
7min amount of flow of water. B) Shear rate observed in devices containing 2,3
and 4 legs after 7min amount of flow of blood. n = 5 for both water and blood.
As the characterisation of flow within DDF chips was carried out using
water, it was important to understand how the transition to blood would
affect the flow rate and therefore the shear rate. Figure 4.2 shows the
maximum shear rate of the 2 , 3 and 4 leg designs, in both water and blood.
As the characterisation of flow within DDF chips was carried out using
water, it was important to understand how the transition to blood would
affect the flow rate and therefore the shear rate. While blood plasma is
mostly water it is also formed from elements including red cells, white cells
and platelets, and proteins such as fibrinogen and albumin. Red cells have
the greatest effect on viscosity under normal conditions with blood being
about 1.8-times more viscous than water at the same temperature. An
Increase in red cell haematocrit leads to a non-linear increase in relative
viscosity, with a doubling in haematocrit levels more than doubling relative
viscosity [2, 3].
To measure the effect of changing the fluid used from water to blood
the maximum obtainable shear rate for the 2 , 3 and 4 leg designs in both
water and blood are shown in Figure 4.2 . The viscosity (µ) is not constant
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for blood within the channel of the 2, 3 and 4 leg channel as the maximum
recorded shear rate was less than 50s−1, given that µ is not constant for
blood at shear rates less than 50s−1 (detailed in Chapter 2). The 4 leg
channel gave the highest shear rate in both water and blood. When the
shear rate in water was compared to that of blood for all channels, the
observed rate was lower in blood. The results indicate that while the shear
rate is lower in blood the addition of legs to any new chip design can make
up for the difference in the µ and increase the shear rate so that the µ can
be considered constant. The decrease in flow rate (from a maximum) as the
channel fills was similar for both blood and water with the maximum shear
being obtained for 5 − 10 s. As the length of the channel was increased
this slope was more gradual, thereby increasing the bandwidth at which the
shear rate is at or near to its maximum.
The addition of legs also has the advantage of reducing the size of any
prototype chip. With an understanding of how blood will affect the shear
rate, the multi-leg degas chip is ready for integration with an assay that
requires a controlled shear rate.
4.2 Design of DDF Devices to Integrate iPA
iPA is detailed in Section 1.3 and uses the adhesion of platelets to 6 µm
fibrinogen dots, to detect the adhesion of individual platelets and therefore
the percentage platelet adhesion . While iPA has been successfully demon-
strated for the monitoring of patients undergoing anti-platelet therapy it
has not yet been integrated into a chip [4]
Parallel Plate Flow
In order to rapidly establish if the iPA assay could be adapted for integration
into a DDF device a series of parallel plate flow (PPF) experiments were
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undertaken over a range of shear rates. The governing principles behind
PPF are detailed in Section 2.1.1. To create the required shear rate within
the channel a syringe pump was calibrated to insure the flow rate indicated
by the pump equalled that of the blood within the PPF chip.
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Figure 4.3: The % of occupied spots for 5 mm PPF channel at 20, 50, 100,
150 s−1 alongside the results for the iPA assay. n = 5
Figure 4.3 shows the resulting % of occupied spots within a 5 mm PPF
channel for 10 min where blood was flowed to create a shear rate of 20 s−1,
50 s−1 and 100 s−1, results for the iPA assay are also shown. As the shear
rate was increased the resulting adhesion decreased from 53 % to 26 % for
shear rates between 20 s−1 and 100 s−1 with 3 % adhesion for a rate of
150 s−1. These results indicate that the DDF device should maintain a
shear rate between 20 s−1 and 100 s−1 for 10 min in order to detect the
adhesion of platelets. As the lower shear rate gave a marginally higher %
of occupied spots, it was selected when making further comparisons within
the PPF channels tested.
The PPF chip utilises a channel length of 42 mm with the 6 µm spots
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Figure 4.4: The % of occupied spots for 5 mm PPF channel when the array
was printed at the inlet, centre and outlet. n = 7
printed half way along this channel with a 6 mm inlet and outlet. To
determine if the channel inlet or outlet have an effect on platelet adhesion
the array was printed at the inlet, middle and outlet. Figure 4.4 shows
the resulting % of occupied spots alongside the diagram of the channel and
placement of the array. The results show no significant difference across the
channel and indicate the full length of the channel can be used to detect
the adhesion of platelets.
The effect of changes in channel width on the adhesion of platelets in
6 µm spots are detailed within Figure 4.5-A, for channels of 4, 5, and 6 mm.
The results show little difference between % of occupied spots for the 5 or
6 mm channels and low adhesion in channel widths below 4 mm, indicating
that platelet adhesion can be affected by channel width. This difference
could be as a result of the lower flow rate required to achieve the same
shear rate as the width is decreased, thereby resulting in red blood cells
settling on the surface of the channel. Figure 4.5-B shows the resulting %
for a 5 mm wide PPF channel after 3, 6, 9, 12 and 15 minutes, these results
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Figure 4.5: Optimisation of conditions in the parallel plate flow devices for
platelet adhesion to surface coated 6 µm spots of fibrinogen. (A) Adhesion of
platelets (% occupied dots) to 6 µm dots of fibrinogen measured after 9 mins of
blood flow in parallel plate flow device containing channel widths of 4, 5, 6 and 7
mm at a shear rate of 20 s−1 ( n = 5). (B) Time-dependent adhesion of platelets
(% occupied dots) to 6 µm dots of fibrinogen using 6 mm wide channel at a shear
rate of 20 s−1 (n = 5).
show a plateau in the % platelet adhesion occurred after 9 minutes. Five
PPF chips for each of the three widths were tested (n = 5) at 20s−1 and
five chips at each of the different time intervals (n = 5).
PPF has successfully shown a single platelet can adhere to the 6 µm spot
used within the iPA assay. Using the result obtained when testing PPF a
starting point for the design of a DDF channel should include a shear rate
between 20 s−1 and 100 s−1, a channel width no less then 5 mm and a flow
time greater than 6 minutes.
Chip Design
Figure 4.1 demonstrated how the shear rate within a DDF device could
be increased with the addition of legs to a straight channel. With this in
mind, a series of multi-leg DDF devices were designed to investigate if the
parameters established during the testing of the straight channel PPF device
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could be matched. The DDF chip designs were divided into two areas, a
test area and pumping area. The test area contains the assay region and
starts at the inlet, before connecting with the pumping area. By adding
more legs within the pumping area the available area of exposed PDMS is
increased, resulting in an increased shear rate across the assay region. The
assay region contains the array of 6 µm spots. Figure 4.6 shows the final
prototype devices tested, consisting of a 6 mm wide test region with 1, 2,
3, 6, 7 and 9 legs to make up the pumping area.
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Figure 4.6: 2-D representation of the six channel designs created with 1, 2, 3,
6, 7 and 9 legs each of 2 mm width. The green square shows the location of the
6 µm spot array, along the 6 mm width test area. The array contains 24336 spots
made up of 144 blocks of 13× 13 spots.
The test area was placed at the side of the chip to reduce chip size and
better match the channel length used in parallel plate flow. The length
of the channel also reduced any impact upstream changes in flow, caused
by the curved section, may have on the resulting platelet adhesion. Each
leg was increased from 1 mm to 2 mm in width to ease manufacture and
simplify the design. When whole blood was added to the 1, 2 and 3 leg chips
the blood flow was slow, resulting in separation of the blood into red blood
cells and plasma. The DDF chip consisting of 9 legs was found to allow
the blood to flow without separating. The volume of blood loaded onto the
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chip was increased from 100 µl to 200 µl to ensure that a sufficient volume
of blood passed over the µ-contact printed fibrinogen surface, during the 9
minute assay time.
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Figure 4.7: Shear rate profile for 9 leg device. The shear rate decreases from
a high of approximately 120 s−1 to 10 s−1 after 8 minutes. The shear rate stays
between 100 s−1 and 20 s−1 for 5 minutes which is between the range of shear
rates determined with the use of parallel plate flow for adhesion of platelets to
6 µm spots. n = 7
After evaluation of the PPF designs the % platelet adhesion (60%) for
the 6mm by 9 leg was equivalent to the maximum achieved within parallel
plate flow (65%). The flow characteristics differ between the PPF and
DDF devices, with the shear rate of the DDF device decreasing (from a
maximum) over time while the shear rate remains constant within a parallel
plate flow device (controlled by a syringe pump). Figure 4.7 shows the DDF
shear rate profile for the 9 leg channel recorded over 9 minutes, shear rates
ranging from approximately 20 s−1 to 100 s−1 are highlighted. The PPF
chip required a flow time greater than 6 minutes for the same range of shear
rates, while the PPF maintained this rate for approximately 5 minutes, and
10 s−1 to 100 s−1 for 8 minutes. The difference in the time required for an
equivalent result in platelet adhesion could be as a result of the different
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flow characteristics between PPF and DDF flow. The maximum shear rate
of 120 s−1 is achieved during the first 60 seconds of flow and closely match
those obtained from PPF devices. When the channel width (test area) was
decreased from 6 mm to 2 mm no platelet adhesion was observed, given
that the shear rate is the same for both channels this result indicates that
the channel width (at the test region) for both PPF and DDF devices affect
how platelets adhere to 10 µm fibrinogen dots.
4.2.1 Effect of Anti-platelet Drugs Use of iPA
The 9 leg second generation device has successfully been used to measure
platelet adhesion in whole blood from healthy donors but to-date the use of
DDF for the determination of platelet adhesion in patient samples remains
unproven. To determine if this design is suitable for use as a prototype de-
vice for the testing of anti-platelet therapies, platelet reactivity was tested in
both the presence and absence of Cangelor (added in-vitro to whole blood).
Adenosine diphosphate (ADP) was used as an agonist in this assay as it
induces aggregation in whole blood through the activation of P2Y1 and
P2Y12 receptors. Cangrelor inhibits the P2Y12 pathway of activation and
therefore hinders ADP induced aggregation of platelets. Figure 4.8 shows
results for untreated and treated blood allowed to flow in the DDF device
for 9 minutes, after which the % adhesion was calculated. As expected, the
percentage of platelet adhesion was significantly decreased when the blood
was treated with ADP resulting in a 7% occupancy when compared to the
untreated whole blood at 59%. This effect was almost completely negated
after the addition of Cangelor to the ADP treated blood resulting in a 50%
adhesion. Aggregates do not stick to the 6 µm fibrinogen dots patterned
within the test region (when the blood is ADP treated) but instead out
compete the fibrinogen spots on the surface for any single platelets remain-
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ing within the blood, resulting in a decrease in % platelet adhesion. This
effect is reversed if aggregation is hindered by the anti-platelet drug in this
case Cangelor. This DDF design is therefore ideal as a prototype rapid
self-powered device, with enormous potential for use in the point-of-care
assessment of platelet reactivity during anti-platelet therapy.
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Figure 4.8: (A) Detection of in-vitro P2Y12 inhibition using DDF device.
Platelet adhesion to fibrinogen dots (% occupied spots) in 3 separate blood draws
on separate days for a single healthy donor with no agonists with 20 µM ADP,
and with 20µM ADP in the presence of 10 µM cangrelor, which effectively ab-
rogates the ADP effect, demonstrating detection of P2Y12 inhibition. Error bars
represent standard deviations for the 3 separate blood draws. (B) Photos of the
chip during flow and a picture of platelets adhered to the spots used to calculate
the % adhesion are shown in Figure4.8-B.
4.2.2 Discussion of Results
The ability to control flow rate, and therefore shear rate, within a single
channel, was well documented within Chapter 3. Although this flow is non-
linear over time the self-powered and low cost nature of DDF devices render
them ideal for use in a limited resource environment. By successfully demon-
strating the iPA assay the device design offers a prototype with enormous
potential for use as a point-of-care assessment device in 9 minutes. The op-
eration and cost of the 9-leg prototype device compares well when matched
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against light-transmission platelet aggregometry, which requires the blood
to be centrifuged to produce the platelet poor plasma (PPP) and platelet
rich plasma (PRP) required. While the VerifyNow works in whole blood it
has not yet been proven an effective test for use with anti-platelet therapies,
with two large scale studies reporting no significant improvement in clinical
outcomes [5, 6]. The increased complexity of the channels required a differ-
ent approach when removing the PSA channel from the backing sheet and
as a result many of the first attempts failed to seal with the substrate or
blood leaked around the inlet.
As a means of rapidly determining if single platelets would adhere to
6 µm spots a number of different flow rates and shear rates were tested
with the use of a parallel plate flow (PPF) channel. The flow rate, shear
rate and volume of blood can be controlled through changes in channel
geometry and PPF also removed any effects of the decreasing flow rate, and
thus shear rate, seen in DDF devices. The PPF results indicated a 6mm
channel at a shear rate of between 20 s−1 and 100 s−1 would give the best
results. This result differs with data published by Hansen et al. in which it
is stated that a spot size of greater than 20 µm was necessary to support
stable platelet adhesion at a wall shear rate of 300 s−1 [7]. This difference
may be accounted for by the channel size used within the study of only
250 µm or the assay time of 5 minutes.
The device was used to successfully detect the inhibition of platelets in
blood treated with Cangrelor in the presence of ADP and correlates well
with the results published by Lopez-Alonso [4], these results were obtained
using the iPA assay and also expressed in terms of % of occupied spots. The
DDF result also shows the enormous potential of the device to be developed
as part of a point-of-care system for the assessment of platelet reactivity
during anti-platelet therapy. At present no other self-powered device has
been shown to detect the inhibition of platelets. While the device was
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demonstrated with anti-platelet therapies it could be readily adapted for
use with other platelet assays that require a simple way to count platelets,
in remote locations or limited resource environments, such as the developing
world. By changing channel geometry it is possible to create a device with
a defined upper and lower shear rate range. These devices may have a use
within a shear dependent assay outside an area concerned with platelets.
4.2.3 Conclusions
A novel micro-fluidic device was developed for the assessment of platelet
reactivity during anti-platelet therapy. This device has many desirable at-
tributes required in a point-of-care device including portability, ease of use,
speed, low cost, self-powered and low blood volume requirements. DDF
devices do not require an external pump to drive blood flow through the
micro-fluidic channel, resulting in a hand held compact device which could
be used in a clinical setting. A simpler system design is possible as DDF does
not require an external power supply. The use of poly(cycloolefin) sheets
enabled leakage-free blood flow and a smooth blood flow was observed even
at low shear rates, such as 20 s−1 for 10 minutes, which is challenging using
a syringe pump. Although, adhesion of platelets to 6 µm fibrinogen spots
is dependent on the shear rate of the blood flow in DDF chips, test chan-
nel width also had a crucial impact on platelet adhesion. The challenge of
controlling the shear rate in DDF was successfully surmounted by changing
the cross-sectional area of the pumping region and high platelet adhesion
was achieved for the chips with large pumping areas. This DDF device for
whole blood assays points the way toward a new approach for lab-on-a-chip
research as well as point-of-care and high-throughput screening systems for
platelet adhesion studies. This device has the potential to facilitate the
personalisation of antiplatelet therapy particularly for patients with cardio-
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vascular diseases and thus reduce the risk of thrombosis or bleeding in these
patients. However, like the VerifyNow cartridge the prototype DDF chip
is limited to a single agonist. With many individuals on dual anti-platelet
therapy the prototype can only test the effect of one of these anti-platelet
drugs. With this in mind an alternative chip was developed, based on the
rocking table currently used within the iPA assay. This chip allows for multi
agonists to be tested at the same time and is detailed in the next chapter.
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Chapter 5
Integration of an iPA assay
into a Prototype Device for
Point-of-Care
5.1 Introduction
In the previous chapter, the iPA assay (described in Section 1.3) was suc-
cessfully combined with a degas-driven flow (DDF) prototype to create a
self-powered, low-cost and easy-to-manufacture chip. The iPA assay has
been shown by Lopez-Alonso et. al. to correlate well with both Light
Transmission Aggregometry (LTA) and the VerifyNow system [1]. LTA is
detailed in 1.2 and requires a whole blood sample to be processed to create
platelet rich plasma (PRP) and platelet poor plasma (PPP). Both the iPA
and DDF chip are unsuited for use as part of an integrated point-of-care
(POC) device as they require a number of manual blood handling and wash-
ing steps. The iPA assay requires the slide to be placed into a petri-dish
before 1 ml of blood is added and the dish is rocked for 30 minutes. The
slide must be removed from the dish and the platelets washed and stained
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before imaging. For the iPA assay to be part of any prototype device, these
manual steps will need to be automated or removed in order to reduce the
risk to the operator when working with blood.
This chapter details the development of two new chip designs and intro-
duces a chip optimised version of the current iPA assay (COiPA). The first
design is intended for research use and still requires the blood to be manu-
ally pipetted into each well, while the second design integrates a standard
blood handling system and can be used as part of a prototype point-of-care
device. These new designs allow for multiple anti-platelet drugs to be inves-
tigated on a single chip, giving the new design an advantage over the DDF
prototype, VerifyNow system and LTA.
5.2 Optimisation of the iPA Assay
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Figure 5.1: Open square well chip compared with current assay. (A) The seesaw
rocking table used in the current iPA assay can hold 25 samples, the equivalent
to only two square-well chips. (B)The chip fits on a standard glass slide chip and
contains 14 or 16 wells in two rows of 7 and 8, respectively. (C) A 16 well chip
filled with 25, 50 and 100 µl of blood shows how 25 µl fails to cover the surface of
the well and 100 µl fills the well completely, thereby preventing the blood from
moving over the surface.
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The chip was developed to fit a standard microscope slide measuring
75 mm × 25 mm, thereby replacing the 20 × 20 mm cover slip used within
the iPA assay. This change allowed 14 samples to be assayed on a single
chip with 2 × 7 wells measuring 9 × 9 mm. This well size was chosen
to fit the stamp used to µ-contact print the array of 6 µm spots onto the
slide and left some free space around the edge to allow for any alignment
error during printing. The wells were cut into a transparent thermoplastic
sheet of 2.5 mm Poly(methyl methacrylate) (PMMA) with the use of a
laser cutter. A pressure sensitive adhesive (PSA) gasket was then adhered
to one side of the PMMA before final assembly of the well layer and the
glass substrate. Figure 5.1-A shows the rocking table with 24 petri-dish,
each dish contained a single cover slide submerged in 1 ml of blood. A
single test can be carried out with each cover slide and is equivalent to a
single well within the chip.
Optimisation of Blood Volume and Rocking Speed
When the results for both the 14 well chip and petri dish were compared a
lower % adhesion to the spots of fibrinogen was observed for the chip. Given
that the blood volume and rocking speed for the iPA assay has already been
optimised (for a petri dish) it was necessary to determine if these values
were optimal for use with the 14 well chip. A range of volumes from 25 to
100 µl were selected with the results shown in Figure 5.2-A, each well holds
a maximum of 100 µl. Once the blood volume was determined the chip
was rocked at a series of different rocking speeds with the results shown in
Figure 5.2-B.
Out of the five different volumes of blood tested the highest % platelet
occupancy was recorded for 50 µl at 78%. For volumes of 60, 80 and 100 µl
the value decreased from 68 to 30%, while the % platelet occupancy for 25 µl
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Figure 5.2: Optimisation of chip. (A) Five different volumes of blood were
tested from 100 to 25 µl within the well of the chip and the % platelet adhesion
recorded for each volume, with the highest achieved at 50 µl. (B) With the
volume optimised the effect of rocking speed on platelet adhesion was tested at
30, 60and100 oscillations per minute with 50 µl of blood.
was 57%. The bottom well surface was not fully covered with blood when
rocked with volumes less than 50 µl. The reduction in % platelet occupancy
for volumes greater than 50 µl could be a result of how the blood flowed
within the well as the table rocked. The difference in area of the square
well and the area for the petri dish used in iPA (962 mm2) could affect
how blood flows over the surface. Figure 5.2-A indicates that the volume
of blood plays a role in adhesion. The speed of rocking was optimised with
each well filled with 50 µl of blood. Figure 5.2-B shows the results after the
chip was rocked for 30 minutes at 30, 60, and 100 oscillations per minute.
The results indicate the optimum speed is 30 oscillations per minute. This
result compares well with the results published by Lopez-Alonso et al. who
found an optimum speed of 35 oscillations per minute over 30 minutes.
To differentiate the now optimised assay from Individual Platelet Ad-
hesion (iPA) it was given the acronym COiPA (Chip Optimised Individual
Platelet Adhesion). The COiPA assay was combined with a cyclo olefin
polymer (COP) substrate and tested to determine if this grouping was suit-
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able for use as a prototype device for testing antiplatelet therapies. A
comparison between COP and glass is detailed in Appendix E and shows
a comparable level of platelet adhesion. The COP substrate was selected
as it has a number of advantages over the glass substrate currently used,
its low cost, availability in any size, ability to be cut to shape and optical
properties make it ideal for use in a point-of-care chip.
COiPA Tested With P2Y12 Inhibitor
The COiPA assay allows for the capture of single platelets onto an array of
fibrinogen spots and is derived from the iPA assay detailed in Section 1.3.
To demonstrate an in-vitro drug effect using COiPA the agonist, adeno-
sine diphosphate (ADP) was used; this receptor acts on the P2Y12 platelet
receptor,( a list of platelet receptors is listed within Appendix A). The anti-
platelet drug Cangelor can reverse the effect of the agonist by inhibiting the
P2Y12 pathway and therefore hinders ADP-induced aggregation of platelets.
The addition of ADP will result in a decrease in % platelet occupancy, when
compared to untreated blood, as aggregates do not stick to the fibrinogen
array with only a single platelet captured by each 6µm spot [1]. Figure 5.3
shows the resulting % platelet occupancy for an untreated sample of whole
blood, whole blood treated with ADP and whole blood treated with ADP
+ Cangrelor.
As expected the percentage of platelet adhesion was significantly de-
creased for a ADP treated blood sample (15%) when compared to the un-
treated whole blood at 73%. This effect was almost completely negated
after the addition of Cangelor to the ADP treated blood, resulting in a 59%
occupancy. COiPA shows the same trend when Cangelor and ADP was
tested within the DDF prototype device, detailed in Figure 4.8 . Both the
COiPA and DDF devices require 50 µl of whole blood. These results show
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Figure 5.3: Detection of in-vitro P2Y12 inhibition using square wells (50 µl of
whole blood per well). Platelet adhesion to fibrinogen dots (% occupied spots).
The three columns show the result for untreated whole blood, blood treated with
an agonist (20 µM ADP), and ADP in the presence of 10µM Cangrelor (which
effectively abrogates the ADP effect). This is the same agonist and drug shown
in Figure 4.8.
that the multi-well chip can detect P2Y12 inhibition, with a smaller blood
volume on a single chip when compared to iPA which requires 1 ml per
assay.
Effect of Flow Length on % of Occupied Spots
During the testing of the multi-well chip a lower % adhesion was observed
when compared to the petri dish used within the iPA assay. This result
indicated that flow length or well shape may play a role in platelet adhesion
and would need to be optimised. The flow length is defined as the distance
the blood can move from one boundary to the next which in the case of
a petri dish (as a cylinder) remains fixed, despite its rotation when placed
on a seesaw rocking table. The flow length of the well (square in shape)
is dependent on the rotation of the multi-well chip, relative to the axis of
movement of the rocking table. To evaluate if flow length had any effect
on platelet adhesion, chips were placed at both the centre and edge of the
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rocker at an angle of 0o and 45o.
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Figure 5.4: Effects on % platelet adhesion as a result of changes to flow length.
(A) The square well at both 0o and 45o and the difference in flow length. (B)
Effects on % platelet adhesion for a square well placed at both the middle and
edge of the table, at an angle of 0o and 45o.
Figure 5.4-A illustrates how the rotation of the square well affects the
length the blood can flow. When the chip is rotated by 0o the flow length
(a) is at a minimum and at 45o the flow length (b) is at its maximum. The
rocking table moves about a single axis of rotation from its centre and as
a result the blood only moves perpendicular to this axis within the bounds
of the assay well or petri dish.
Figure 5.4-B shows the % adhesion for wells at an angle of 45o and 0o,
placed at both the centre and edge of the rocking table. The results show
no significant difference in the % adhesion between placing the chip at the
edge or centre of the rocking table, indicating the placement of the chip has
no effect and as expected is in line with the iPA assay were the whole table
is used. There is an increase in the % on occupied spots recorded between
the chips placed at 45o and those placed at 0o. The flow length for a straight
well (0o) is 7.3 mm and 9.6 mm for the well at 45o, a maximum difference of
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only 2.3 mm, indicating that flow length is an important design component
and required optimisation.
COiPA Within A Closed Well
For the chip to be used in a clinical environment, it must be safe to use. The
current iPA assay uses an open petri dish, requiring manual blood handling.
COiPA reduced the blood volume need but still requires the same number
of manual blood handling steps, when used with an open well configuration.
For COiPA to be used within a point-of-care device the chip must be sealed
to reduce any possible contact between the operator and the blood. To
address this challenge both an open and closed chip were tested with the
same volumes of blood.
Unlike the open chip, the blood is closed within the well and cannot
move from side to side with the same ease. To test the effect blood volume
has within a closed chip a cover plate was placed over the chip and a hole
was positioned above each well, allowing a different volume to be added to
each well.
Figure 5.5 shows the resulting % occupancy when two different volumes
of blood are added to both an open and closed well. For a volume of
50 µl there is no significant difference between the two well configurations.
However, when 110 µl (completely full) of blood was pipetted into each
well type and rocked a decreased adhesion of 45% and 0% were recorded for
the open and closed wells, respectively. These results indicate the volume
has an effect on the resulting adhesion and the assay requires the upper
surface of the blood to be able to move freely. Therefore, any closed chip
will require a method to deliver a controlled volume to each well.
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Figure 5.5: Comparison between open and closed chips. The assay wells of
both the open and closed versions of the chip were loaded with 50 µl and 110 µl
of blood and the % of occupied spots recorded. The corresponding images of the
protein spots and the platelets adhered to these spots are also shown.
5.3 Prototype Design
The results obtained for the multi-well chip highlighted a number of key
design components that would need to be optimised for any new prototype
point-of-care device. Different well shapes were tested to increase the %
platelet adhesion of COiPA, to better match the iPA assay. Different sys-
tems were also tested to allow a fixed volume of blood to be delivered to
each well (detailed in Appendix E).
Optimisation of Well Shape
A series of well designs were evaluated to determine the best shape required
to maximise platelet adhesion when using COiPA. The effect of the height
of blood within the well, as the table rocked, was also investigated and is
detailed in Appendix E.
In total five different well shapes were evaluated, four of the same ca-
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Figure 5.6: Effects of channel shape on platelet adhesion. Five different shaped
wells were tested each with different flow lengths, results shown are for wells at
their maximum flow length. The maximum % platelet adhesion was recorded for
the small rectangle. One of each well type (numbered 1-5) was tested using the
same whole blood sample, this was repeated five times (n=5) with a total of 25
chips tested
pacity and one larger capacity rectangle. Figure 5.6 shows results and illus-
trations for each well type starting with the square used with the multi well
chip alongside a circle, oval and small rectangle. The larger capacity well
has the same flow length and maximum width and was included as a well
shape to make a comparison between wells of equal flow length and a well
with the maximum width equal to that of the oval. A 60% occupancy of the
6 µm spots was recorded for the small rounded rectangle, over twice that
recorded with the square well. The results also show no difference between
the oval, circle and square wells with both the rectangular wells performing
significantly better, with the lower capacity well giving the best outcome.
Well shape 5 (shown in Figure 5.6) gave the highest resulting adhesion of
the five shapes tested and was therefore selected for further optimisation..
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Rectangular Well Optimisation
To determine the effect on the % of occupied spots when the well (well type
5) is closed, a lid was added to the chip. A range of blood volumes from
50 µl to 100 µl was tested in both the presence and absence of the lid.
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Figure 5.7: Optimisation of blood volume within rectangular well. Four differ-
ent volumes of blood were tested from 70 µl to 100 µl in increments of 10 µl for
both an open and closed well. No statistical difference in the % of occupied spots
was recorded for the open well.
Figure 5.7 shows no statistical difference between volumes from 50 µl
to 100 µl for the open well. When the closed well is considered the %
of occupied spots is approximately 10 % for volumes greater than 70 µl
within the closed chip. This result shows that blood volume is of greater
importance when designing a chip with a closed well configuration.
When the % of occupied spots between well type 5 and the iPA assay was
compared a, reduction in adhesion of platelets within the well was observed.
To address this difference the flow length of the well was increased to match
that of the petri dish. Figure 5.8 shows the two well types used alongside a
comparison of the % of occupied spots between the iPA assay and COiPA,
well type 6 has double the flow length of well type 5. The results show a
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Figure 5.8: Optimisation of flow length. A channel with the same flow length
as the petri dish (38 mm) is compared alongside a glass slide and APTES treated
Zeonor (shown in red). The 17 mm (Well 5) long channel is the is the same as
that shown in Figure 5.8.
comparable % of occupied spots between well type 6 (75%), and the iPA
assay using a glass substrate (88%) and APTES treated Zeonor substrate
(79%). The results show that by matching the flow length COiPA with
that of the iPA assay that well type 6 offered a comparable assay with a
reduced blood volume within a smaller form factor, making it ideal for use
within the two prototype chips described below. The ability to use the
COiPA assay in the closed well configuration allows for an integrated blood
handling system to be included in the chip design.
5.3.1 Research Chip
Blood handling is an important consideration when designing a new pro-
totype device and requires all wells within the chip to be closed. For this
reason both prototype chips are only available in the closed well configura-
tion and utilise the optimised well design. The first prototype, known as
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the research variant, allows for in-vitro testing of multiple drugs within a
single chip and is available with 4, 8 and 12 wells. The second prototype
integrates a blood handling system and allows for a fixed volume of blood
to be delivered from a staging well to each assay well at the same time
Optimisation of Blood Volume in Research Chip
The difference between the open and closed well designs was overcome by
increasing the well height from 2.5 mm to 6.0 mm; this allows the blood
to flow freely from one end of the channel to the other. When smaller
volumes of blood (< 50 µl) were rocked within well type 6 the blood did
not cover the printed area completely, requiring the volume of blood to
be again optimised. Figure 5.9-A shows the result of the three different
volumes of blood tested, when compared to the iPA assay and increasing in
increments of 50 µl from 100 µl to 200 µl.
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Figure 5.9: A) iPA assay compared to research chip filled with 100 µl, 150 µl
and 200 µl of blood. B) Pictures illustrating how the chip is filled and the flow
length of the iPA assay and chip can be compared.
A difference of 3% was recorded for volumes of 150 µl (78%) and 200 µl
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(81% ). Therefore, a volume of 200 µl was selected for use with both the
research and integrated chip. This decision also allowed for the simplifica-
tion of the blood delivery system used within the integrated chip, giving a
possible range between 150 µl and 200 µl before the results are significantly
affected. Figure 5.9-B illustrates how the research chip is filled, a picture of
the petri dish used in the iPA assay is also shown alongside the full chip. It
is clear from this picture how the flow length for the chip matches that of
the dish and how the space used by four wells is equivalent to a single petri
dish.
Research Chip Tested With P2Y12 Inhibitor
Figure 5.10-A shows the comparison between the iPA assay (88%) and the
research chip (81%) for 3 donors (12 wells per donor). This result shows
that the combination of well type 6 and 200 µl volume of blood can give a
comparable % platelet adhesion to that of iPA. Figure 5.10-B shows the re-
sulting % platelet occupancy for an untreated sample of whole blood, whole
blood treated with ADP and whole blood treated with ADP + Cangrelor.
The percentage of platelet adhesion was significantly decreased when the
blood was treated with ADP resulting in a 5% occupancy when compared
to the untreated blood at 78%. This effect was almost completely negated
after the addition of Cangelor to the ADP treated blood, resulting in a 74%
occupancy, showing the research chip can detect P2Y12 inhibition. This
result follows that observed when testing drug effect using the iPA assay,
showing the research chip’s low blood volume, closed well, low form factor
and multi well design can be used as an alternative iPA assay.
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Figure 5.10: A) Comparison between iPA and COiPA. B) The detection of in-
vitro P2Y12 inhibition using the research chip. B) Platelet adhesion to fibrinogen
dots (% occupied spots) in 4 healthy donors in whole blood, whole blood + 20 µM
ADP, and with ADP in the presence of 10µM Cangrelor. (n = 5)
5.4 Design of Integrated Chip
The research chip was further developed to allow for an integrated blood
handling system to be used; the new design has the same well type as the
research chip and includes two new layers. The introduction of a staging
well allowed for a fixed volume of blood to be delivered to each assay well,
while an existing blood handling technology manufactured by Sarstedt AG
& Co was added to the chip. The blood can be collected from a patient
using a disposable needle into a syringe containing an anti-coagulate; with
the use of a connecter fitted to the chip, the blood is transferred from the
syringe to four staging wells.
Figure 5.11 shows the syringe which has been designed to be compatible
with a number of different connectors. The connections allow for both a
needle to be connected enabling blood draws from patients, and blood to
flow into the prototype device. A large number of iterations of each design
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Connector
Needle
Monovette Syringe
Figure 5.11: Monovette System used with device.
were required to address the issues with the previous version, with a total
of six major versions of the chip detailed in Appendix E.
Flow Path Of Blood Within Integrated Chip
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Figure 5.12: The final version of the chip. (A) The four layers that make up
the chip excluding the Zeonor substrate and PSA gaskets. (B) A detailed view
of each layer with the important features indicated.
Figure 5.12 shows the four layers of the integrated chip alongside the
drawing of each layer detailing the key geometric features. The staging and
assay wells are present within both layer 3 and 4, giving a total well height
of 6 mm, which matches that of the research chip. The blood enters the
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staging well within layer 4. Once all wells are full the blood passes through
the fill channel within layer 2 and enters into the top of the assay channel.
The shape of the fill channel was optimised to encourage the blood to spread
as the channel is filled. This flow path reproduces how the research chip is
filled, making it possible to compare results across the two chip types.
Staging Wells
Figure 5.13 shows how the blood passes from the syringe through the con-
nector into a series of bifurcations, each delivering a single source of blood
to each of the staging wells. The variability in the viscosity of blood and
surface tension of blood was one of the biggest challenges when trying to
deliver a fixed volume to the assay well. Surface tension γ is the magnitude
F of the force exerted parallel to the surface of a liquid divided by the length
L of the line over which the force acts, with units of N/m [2].
γ =
F
L
(5.1)
The staging wells address both of these challenges with the use of geo-
metric features and surface tension, stopping blood from leaving the staging
well until each well is completely full. While the blood enters the well from
the side it exits through the outlet at the top of the well. The outlet was
designed to create a resistance to flow greater than the total resistance at
the inlet of all four staging wells. The surface tension of the chip allows the
blood to spread across the well as it enters, while the resistance at the outlet
compensates for any small difference between how the blood spreads across
each well. This simple solution has the effect of ensuring that no blood will
leave the staging well before all wells are completely full and allows any one
of the staging wells to start filling before another, removing the need for
any valves within the chip.
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Figure 5.13: The finish chip and how blood is loaded using the syringe to fill
the staging wells.
Not all the blood from the staging well is moved to the assay well with a
small amount left behind, leaving a volume greater than 5 µl and less than
20 µl remaining within the well. The well was designed to hold 185 µl and
the bifurcation < 20 µl, giving a minimum of 185 µl and a maximum of
200 µl within the assay well. With both the research chip and integrated
chip using the same well type these values fit well with the results from
Figure 5.9-A , where no significant difference between < 150 µl and < 200 µl
was recorded. Once all the staging wells are full the syringe is removed
and replaced with a syringe full of air, used to push the blood from the
staging wells into the assay wells. At this point both the research chip and
integrated chip are treated the same for the remainder of the assay.
Fill Channels And Bubble Catcher
The fill channels were tapered from the staging well outlet to the assay well
inlet. This change removed any corners where bubbles may form and also
allowed any bubbles that did form to be pushed to the side where they would
not affect flow. A small bubble catcher has also been added to remove any
bubbles at both the staging and assay well. The catcher traps the bubble as
it moves across the top surface of the chip by blocking its path to movement.
Within the assay well the surface of the bubble in contact with the blood
continues to move with the blood as it is rocked. The movement causes the
bubble to become elongated and burst or splits into two or more easily to
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manage bubbles. Once bubbles do not block the protein surface or restrict
flow within the channel they do not adversely affect the results.
Integrated Chip Tested With P2Y12 Inhibitor
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Figure 5.14: Detection of in-vitro P2Y12 inhibition using the integrated chip.
Three chips used with four wells per chip.
To determine if drug effect could be detected using the integrated chip
an agonist was added to the blood to decrease platelet adhesion to the spots,
an anti-platelet drug was then used to reverse this effect. Figure 5.14 shows
the results closely matching those of the research chip (Figure 5.3), this is
not surprising given that the only difference between the two chips was the
inclusion of a blood handling system to deliver 200 µl of blood to each well.
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As the same blood sample is delivered to each well, the results from
Figure 5.14 required the use of three chips (4 wells per chip) with untreated
whole blood, whole blood and ADP and Whole blood + ADP + Cangelor.
The ADP and Cangelor were added to blood before being placed into sy-
ringes. The integrated blood handling system, size, small blood volume and
ability to easily scale the chip with more wells make the prototype chip ideal
for use as part of a point-of-care system.
5.5 Summary
A number of different well shapes along with their location on the rocking
table were tested to determine an optimal well shape for adhesion of platelets
to 6 µm spots. The results showed a comparable % adhesion between iPA
and COiPA when a rectangular well with rounded ends was used in place
of the petri dish. For each iPA assay performed, over five COiPA assays
could be completed with only 200 µl of blood in each well, allowing for
unused blood to be left in the staging well of the integrated chips. The
results from the early chip designs showed a difference between how blood
flows and behave within a closed environment when compared to water,
complicating the delivery of a sufficient volume of blood to the assay well.
Different iterations of this design aimed to solve these issues, with the final
prototype chip introducing a number of features including; a staging well,
bubble catcher at the inlet and a tapered filling channel. The chip was
successfully shown to detect drug effect and is well suited for use as part of
a point-of-care system.
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5.6 Discussion And Conclusions
This chapter described the different steps required to optimise the iPA as-
say for use within a low blood volume chip and introduced the concept
of COiPA, used to successfully detect the inhibition of platelets in blood
treated with Cangrelor in the presence of ADP. COiPA was also shown
to correlate very well with results published by Lopez-Alonso et. al. [1].
The prototype device is the first to use a matrix of spots for the testing of
anti-platelet therapies and offers a number of advantages when compared
to the VerifyNow , LTA and PFA-100 systems. With further development
lyophilised agonists could be added to each well, allowing for multiple anti-
platelet therapies to be tested at the same time using only 200µl of blood per
well; currently available tests can only test a single therapy at a time. The
VerifyNow is the only other device to integrate a standard blood handling
system onto a cartridge, with a separate cartridge and blood draw required
for each VerifyNow test. The integrated chip would require a single blood
draw to complete multiple tests.
The integrated chip introduced a number of novel features for dealing
with bubble formation and allowing a controlled volume of blood to be deliv-
ered to each well. At the same time, the chip allows for blood to be loaded
using a sharps-safe, integrated connector within a fully sealed disposable
chip. As an early prototype, the chip performance was excellent. However,
there is a need for further development to improve assembly time and re-
duce delamination and leaking as a result of dust or debris adhering to the
PSA during assembly. The current chip design has four assay wells for the
testing of dual anti-platelet therapies, new therapies or different concentra-
tions of an antagonist could be added to the assay with the easy addition of
wells to the chip. Results show the optimised COiPA assay is comparable
to the current iPA assay. The prototype has enormous potential as part
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of a point-of-care system for the assessment of platelet reactivity during
anti-platelet therapy. The requirement to label the platelets to obtain a
result for the iPA assay, has the potential to make any point-of-care sys-
tem complicated, time consuming and costly. For this reason, a new image
technique was developed to allow platelets to be imaged without the need
to first label them. Introduced in the next chapter, this technique reduces
system complication, assay cost and will reduce the assay time.
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System Automation
6.1 Introduction
Both the Individual Platelet Adhesion (iPA) and Chip Optimised Individual
Platelet Adhesion (COiPA) assays require a number of manual steps to
obtain the resulting % of occupied spots. The need to fluorescently label
the platelets after the blood has been rocked and the requirement to count
each platelet adhered in order to calculate the % of occupied spots, all
added to the overall assay time. For each printed area of fibrinogen spots a
number of different regions were imaged, using a fluorescent microscope. By
calculating the % of fibrinogen spots occupied for each image set, an average
value across the full printed area can be calculated. An image set contains
an image of the 6 µm spots and a corresponding image of adhered platelets
to the same area. This chapter introduces a custom built software package
that includes a new automated image processing technique to calculate %
of spots occupied from both the image of fibrinogen spots (red) and the
platelet image (green). The software also performed a number of quality
control checks on the µ-contacted printed protein array.
The prototype device (detailed in Chapter 5) was designed as a closed
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system, making it more suited as part of a point-of-care device. This closed
system created a complexity when trying to introduce the platelet specific
antibodies, required to image the platelets. To overcome the need for la-
belling, a novel imaging technique was developed. This technique removed
the need to label the platelets and only requires images to be taken of the
surface, simplifying the acquisition of results from the assay, reducing com-
plexity, cost and the overall time by 1.5 hours. The label-free detection
method does not require the blood to be treated in any way, or the blood to
be removed from the chip. This technique has practical applications outside
of this project and could be used to detect adhesion of any cell type to a
protein array, potentially allowing for the simplification of existing or the
development of new device assays.
6.1.1 MATLAB Software
While a MATLAB script was available to automate the calculation of re-
sults, it required a number of manual steps, was slow to run, was limited
to a single set of images and required a colour camera. The software was
also unreliable resulting in false positives; these errors occurred as a result
of the approach used and the absence of any quality control of the acquired
images. The user interface was also overly complicated with an ability to
change settings and required the user to manual input each file location.
As the MATLAB script also lacked any version control, when a bug was
fixed there was no way of knowing if the change would affect older results,
requiring the image sets to be rerun through an already time-consuming
process.
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6.2 Matched Feature Methods
The newly developed software includes a number of different methods used
to calculate the resulting % of spots occupied, with each technique tai-
lored for a different need. Each method incorporates blob analysis, used
to determine the location of each platelet and protein spot within the im-
age set being processed. By searching the array image for suitable features
it is possible to check the platelet image for a corresponding feature and
thereby detect when a platelet has adhered to a spot. Two Matched Fea-
ture Methods (MFM) are included in the software. The first offers the
operator a semi-automated interface and allows the % of occupied spots to
be manually calculated. The second is fully automated and only requires
the operator to select the image location on the PC.
Manual Method
Figure 6.1 shows two images side by side after the user has selected the
image set they wish to manually calculate, the % of occupied spots from.
The right hand side of the window shows the image of the platelets and
the left hand side shows the image of the fibrinogen spots. Images were
acquired using a monochrome camera. Feedback colour was added by the
software to make it easier for the user to find both the fibrinogen spots and
platelets. The software uses a Cartesian coordinate system; an object is
highlighted within the figure at location x = 30 and location x = 34. The
software calculates the coordinate for a platelet (from the platelet image) as
the user uses the mouse to select the location by clicking the mouse. As the
mouse is moved across the image, a corresponding cursor moves to the same
coordinate within the spot image. This allows the user to visually determine
if a platelet has adhered to a spot. By right-clicking the mouse the user
is indicating that the platelet has adhered to a spot. The click indicates
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Figure 6.1: Snapshot of window used to manually count adhered platelets to
6 µm spots. The image was captured from within the iPlatelet software, with
the image of arrayed fibrinogen displayed on the left and the platelet image to
the right of the window.
the platelet is not adhered to the spot and therefore should not be counted.
Four crosses encapsulate a 13 × 13 array of spots and were originally
included to allow the user to easily select a fixed number of spots from the
image, used to calculate the % of occupied spots. When the user left clicks
on the platelet a white X is added to mark the location within the platelet
image and a white circle within the matrix image. The location and click
selection is also added to a list box (left hand side of Figure 6.1), allowing
the user to copy the data into an Excel spreadsheet for later analysis.
Automated Method
The automated matched feature method takes advantage of an image pro-
cessing technique called blob analysis [1]. This method converts each feature
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within the image into a matrix called a blob, the blob itself is a binary rep-
resentation of the feature and allows for metadata about the feature to be
calculated. This metadata includes attributes of the feature such as the cen-
tre of gravity (CoG), smallest rectangle to bind the feature, feature shape
and the feature size. A detailed explanation of image processing techniques
is included in Appendix F.
Plateletb
DetectedbAndb
MarkedbWithb
(RedbDot)
SpotbLocationbb
Markedb
WithbCircle
PlateletbAndbSpotb
Overlappingb
b(GreenbDot)bb
Plateletb
WithoutbSpot
CoG
Blob
Blob
Platelet SpotbLocationb
Figure 6.2: Snapshot of window used to calculate the % occupancy for a single
image set using the automated matched feature method (AMFM). The image
was captured from within the iPlatelet software. The image of arrayed fibrinogen
is displayed on the left and the platelet image to the right of the window. The
platelets are marked with a green dot while the corresponding 6 µm spot is
marked with a red dot.
Figure 6.2 shows a section of the platelet image containing two platelets,
alongside the blobs representing each platelet. Each spot within the image
of fibrinogen spots was first converted into a blob creating a blob array,
before calculating the CoG for each blob within the array. This process
was then repeated for the platelet image and the CoG of each spot within
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the blob array was checked to determine if it lies within any blob contained
within the platelet blob array, allowing for the % of occupied spots to be
automatically calculated. A graphic representation for a sample image set
with the CoG of each spot superimposed onto the platelet image is included
in Figure 6.2. It is clear from the platelet image that none of the platelets
that have adhered to the crosses (visible within the matrix image) have been
used when calculating the % of occupied spots. The removal of the need to
use colour images, automated file selection, performance improvements and
version control give this automated method a number of advantages over
the MATLAB script. The removal of the need for a colour microscope may
allow the assay to be imaged using a less expensive microscope, making the
assay easier to use in a non-laboratory setting
Each image set contains both the matrix image and platelet image and
are processed simultaneously with each image set requiring less than a sec-
ond. If the software is not required to render the output image the software
can return a faster result. With at least 4 image sets per well and multi-
ples of each experiment required, there can be a large number of image sets
to be processed at a single time. The software was written with managed
and unmanaged code; when managed code is used the computer memory
is managed by a framework. While managed code has a number of advan-
tages when programming applications with a user interface, it is unsuited
for image processing, requiring the software to use a mixture of the two. If
the image is not rendered the software uses only unmanaged code and can
return results for 50 image sets in about 45 seconds, whereas the MATLAB
script would take about 1 hour in total. This technique also includes a
quality control step. All calculations were carried out using a HP elitebook
8730w with 4GB of DDR2-800 RAM and an Intel Core 2 Extreme QX9300
(2.53GHz) 12MB cache. An NVIDIA Quadro FX 2700M with 512 MB of
dedicated video memory was also available. Computational time is depen-
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dent on computer resources available at the time the program is run, the
hard disk can limit the performance when rendering the image. It takes
approximately 102 s to render and get results for the same 50 image sets
that take 45 s without rendering.
Quality Control Of Spots
Missing 
spot
Fully  printed
spot
Badly Printed  
spot
Figure 6.3: Image of an array of spots showing the output of the quality control
test applied to each spot, a missing, misprinted and fully printed spot are each
highlighted. Missing and misprinted spots are removed from the calculation even
if a platelet has adhered at that location.
By checking the shape of each spot any badly printed spots can be
ignored when calculating the % of occupied spots. Even if a platelet has
adhered to a badly printed spot the software will ignore it. When no spot
is detected any platelet within that area is also ignored. Figure 6.1 shows
the software automation also excluded any platelets adhered to the crosses
found within the image, thereby resulting in the inclusion of only platelets
which have adhered to fully printed spots when calculating the % occupancy
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6.3 Label-Free Detection
Label-Free Detection (LFD) takes advantage of the optical properties of
the Zeonor (Cyclo Olefin Polymer) substrate, allowing for the automated
calculation of the % occupancy from a single image. Developed during this
project, LFD removes the need to handle the blood in order to calculate the
% of occupied spots, which is not possible when one of the feature methods
was used. With no need to label the blood the assay time is reduced by
1 hour and 30 minutes, and the need to design and integrate a system
to label the blood within the prototype device is also removed. While the
technique still required the labelling of the fibrinogen spots, this can be done
when the fibrinogen is µ-contact printed. This method introduced a new
set of challenges, requiring the software to detect the location, despite the
orientation when printed, of each spot within the array. The development
of new post-processing filters was required in order to determine if a platelet
had adhered to a given spot. The method used to detect the orientation of
the array, including the filters used, is detailed in Appendix F
6.3.1 Characterisation of Spot for LFD
An interesting phenomenon causing a decrease in the intensity of the spots
to which a platelet has adhered was observed (within the array image). It
is this phenomenon that makes label-free detection possible. Figure 6.4
shows a comparison between the same region for a sample image set. A
spot of low intensity and high intensity are labelled to demonstrate this
difference, with the light being absorbed by the adhered platelet accounting
for the difference. However, it is also possible that the low intensity spot
could be a result of a badly printed, missing spot, an inconsistency in dye
absorbed by the fibrinogen, or the Alexa-488 dye used with the platelets.
To determine if this was the case the assay was tested without the platelets
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Spot
light source
Platelet
Platelet Image Fibrinogen Array Image
No Platelet
Platelet
Light
Figure 6.4: Images of both labelled fibrinogen and labelled platelets with two
spots highlighted, with and without a platelet adhered. The difference in intensity
makes it possible to determine the of a platelet.
labelled.
Using bright field images taken of the unlabelled platelets along with
images of the labelled fibrinogen, a comparison could be made between the
two. Figure 6.5 shows a section of a sample image set with the platelets
circled within both images. The results show the same difference in intensity
is clearly visible and correlates with the presence of an adhered platelet
within the bright field image, indicating that the labelling of platelets has
no effect on the results calculated using LFD. With the knowledge that
labelling platelets has no effect on the intensity of a spot a method to
automatically test each spot for the presence of a platelet was developed.
Using the technique described in Section F.1.1 a mesh was build and the
region that enclosed each spot location was extracted. With the use of a
newly developed filter the presence of an outer ring, similar to a coffee ring,
was observed within some regions. This coffee ring effect was only present
when no platelet had adhered.
Figure 6.6 shows a selected area of a sample image and the results for
121
P. M. McCluskey
Fibrinogen Array Image Bright Field Images Showing Platelets
Figure 6.5: Two images of a corresponding area using both a cy3 filter and
brightfield. The brightfield image shows platelets are clearly visible and match
spot locations, indicating platelet labelling is not required for LFD.
the LFD method. By applying a custom combined scaling and high-pass
filter (HPF) to each region extracted from the image. The scaling filter
uses the mean intensity for all extracted regions as the scale factor, while
the HPF removes the lower values to reduce noise created as a result of the
scale filter. Any values greater than 255 are set to zero, thereby creating a
black hole at the centre of each unoccupied spot (coffee ring effect). A blob
is extracted from each region and a histogram in both x and y is created.
From the two sample histograms shown in Figure 6.6, the difference between
occupied and unoccupied spots can be clearly defined. Using the resulting
histograms the software divides the spots into two groupings, occupied and
unoccupied.
Second Pass Characterisation
An average curve is created for each group using the unfiltered region; these
average curves allow for an upper and lower band to be calculated. The
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Figure 6.6: Graphical demonstration that combines a mesh alongside the LFD
filter. A) Sample image with mesh applied alongside a region highlighting the
output of the LFD Filter. B and C) histograms for a single spot detailed the
change in output used to classify a spot. The green line shows the curve before
the filter is applied and the red line shows the output curve.
upper band is defined as the intensity value half way between the maximum
intensity values taken from the occupied and unoccupied curves, while the
lower is half way between the upper band and the maximum intensity value
of the unoccupied curve. Any curves that fall inside of the upper and lower
band are removed from the unoccupied group and not included when the
% occupancy is calculated. This step removes those spots that were not
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removed during the quality control of the image and which the filter is
unable to clearly define as unoccupied.
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Figure 6.7: Plot of the average curves used during the second pass characteri-
sation. A) Shows the curves for a 5 × 6 sample array used to calculate the upper
and lower bands. The green curve represents no platelets detected, while the
red curve (lower average intensity) represents adhered platelets. B) An image of
the area averaged with the spots containing platelets circled, alongside a colour
image of a filter used to show the operator which spot LFD may select.
Figure 6.7-A illustrates the average curves for a 5 × 6 sample area of
spots, the results show a significant difference between the curves for the
occupied and non-occupied groups. The area enclosed within the upper
and lower bands is also illustrated to demonstrate the region in which spots
will be rejected. A single image may contain 430 spots and the number
of unclassified spots may be between 4 and 15, giving a maximum error
of approximately 3.5%. An image of the array is included in Figure 6.7-B
alongside a colourised version used to help the operator to identify spots
with and without platelets adhered if they wish to do so.
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Figure 6.8: The resulting % of occupied spots using different detection methods.
Image sets were taken from a single donor and the resulting % of occupied spots
calculated using the available methods.
6.3.2 Results
Figure 6.8 shows results for 6 image sets taken from a single donor with
ADP added to the sample. The % platelet occupancy was calculated using
the four available methods, manual counting, automated matched feature
method (AMFM), AMFM for a 13 × 13 array, and label-free (LFD). It
can be assumed that all adhered platelets were counted manually, allowing
this result to be used as a reference value. The correlation between the first
two methods is excellent with a difference of 0.3%, showing the automated
software can be used to make a reliable comparison. A difference of 1.5%
(standard deviation of ±2.6 ) was noted between AMFM and AMFM Array
(13 × 13 array). There is also no statistical difference between these results
and manual counting, indicating counting of just those spots within the
array is sufficient to calculate the % occupancy. When LFD was applied a
value of 27.6 ±2.8 was calculated. This result compared well with the three
matched feature methods with a maximum difference of 3.5% recorded,
between LFD and manual counting. This difference could be explained by
the spots excluded during the quality control checks carried out during label-
free detection. The detection methods detailed in this chapter are designed
125
P. M. McCluskey
to allow automated results to be calculated for the iPA assay. Given that the
object is to integrate a point-of-care chip with a suitable imaging system,
the advantages offered by LFD make it an ideal candidate, as it allows for a
much simpler system to be designed. The 5.9% difference between manual
counting and LFD could be reduced with additional tuning of the filters.
However, given that any simplified imaging system will require optimisation
and that the result is still within the dynamic range of the assay (50%), there
may be no need for further development of the LFD filters using the current
microscope.
6.3.3 Conclusions
There are a number of commercial and open-source (free) software packages
available for the processing of biological images. However, on investigation
these software packages were not easily adapted to automation of the image
processing required for this project. There are a number of advantages in
using the iPlatelet software over other programs. These include, licence free
use, fast response to feature requests and bug reports, the ability to control
the complexity of the user interface, inclusion of custom hardware control
elements (if required), and the seamless calculation of results in a format
the user requires. The software can also be updated to include encryption,
remote management, user control, and to import results into an existing
database available at the Clinical Research Centre (CRC) which complies
with statutory data protection.
The development of the matched feature method (integrated into the
iPlatelet software) reduced the overall assay time and for the first time
allowed the % occupancy to be calculated in a fully integrated, robust and
reproducible environment.
The method correlates with manual counting and reduces the calcula-
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tion time from 15 minutes to under a second, it was also found to have an
advantage over the MATLAB script, described at the start of the chapter.
With a significant decrease in assay time and the removal of the need for
a colour camera to be used to acquire the image sets, the matched feature
method introduces the possibility that the assay could be imaged using a
low-cost microscope. LFD has been shown to correlate with the three differ-
ent matched feature methods developed and does not require the platelets
to be labelled, reducing the assay time by one and a half hours. The removal
of the need to label platelets allows results to be calculated for the iPlatem-
atrix(iPM) chip without the need to design a delivery system to first label
the platelets. The integration of the iPlatematrix(iPM) alongside LFD has
great possibility for the design of an automated low-cost prototype point-
of-care device, as any imaging system only requires a single filter, thereby
removing the need for complex moving parts and multiple light sources.
LFD also works with the degas-driven flow chip and the iPA assay.
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Conclusions
Two unique BioMEMS systems have been developed and shown to success-
fully test the efficacy of anti-platelet therapies. The first system exploited
the material properties of PDMS to facilitate power-free pumping, while the
second allows for multiple tests to be cared out at the same time within a
single chip. The systems use a new image analysis technique and software
to objectively quantify single platelet binding events, without the need to
label the sample blood. The objectives of this work as described in Chapter
1 were realised.
1. To identify and develop new technologies that can be used to design and
build a single-use prototype point-of-care device to test anti-platelet
therapies.
While the iPA assay had already been shown to detect the efficacy
of anti-platelet therapies [1], it was still time-consuming , required a
high degree of manual steps, and had only minimum assay optimisa-
tion completed. Degas-driven flow had the potential to meet these
challenges as it removed the need for external pumping and allowed
for a prototype single-use chip to be created. A new low cost manufac-
turing technique was developed and characterised. The technique was
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used to rapidly create different iterations of the chip design, before
a final degas-driven device was successfully used to test the efficacy
of anti-platelet therapies. The device demonstrated how degas-driven
flow allowed for a reproducible and controllable flow rate for a given
assay time. This control gives the device potential to be used with
flow based assays beyond platelet function.
2. To develop new image processing techniques that will allow for the au-
tomated quality control of a printed protein surface.
The iPlatematrix device was developed to minimise the iPA assay
within a single-use prototype point-of-care device, dealing with any
bubble formation, while at the same time allowing for blood to be
loaded using a sharps-safe, integrated connector within a fully sealed
disposable chip. The results show the optimised MiPA assay is com-
parable to the current iPA assay and has enormous potential as part
of a point-of-care system for the assessment of platelet reactivity dur-
ing anti-platelet therapy. The addition of wells to the integrated chip
could allow for new therapies to be added to the assay or different
concentrations of an antagonist to be tested giving the integrated chip
potential advantages over the VerifyNow and LTA systems. The devel-
opment of the matched feature method (integrated into the iPlatelet
software) reduced the overall assay time and for the first time al-
lowed the % occupancy to be calculated in a fully integrated, robust
and reproducible environment. The method correlates with manual
counting and reduces the calculation time from 15 minutes to under
a second. With a significant decrease in assay time and the removal
of the need for a colour camera to be used to acquire the image sets,
the matched feature method introduces the possibility that the assay
could be imaged using a low cost microscope.
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3. To develop a technique to automate acquisition of results from complex
protein arrays used with the prototype device.
Label-Free Detection (LFD) has been shown to correlate with the
three different matched feature methods developed and does not re-
quire the platelets to be labelled, reducing the assay time by one and
a half hours. The removal of the need to label platelets allows results
to be calculated for the iPlatematrix(iPM) chip without the need to
design a delivery system to first label the platelets. The integration
of the iPlatematrix(iPM) alongside SLD has great possibility for the
design of an automated low-cost prototype point-of-care device, as
any imaging system only requires a single filter, thereby removing the
need for complex moving parts and multiple light sources.
7.0.4 Future Work
Although both systems have had been shown to successfully test the efficacy
of anti-platelet therapies there is still room for further developments, that
could improve overall functionality of the systems.
Integrated chip
While the layers of the chip are currently laser cut in-house, if a large number
of chips are required it may be necessary to have a commercial operator
cut and assemble the parts. This change could require both aesthetic and
functional design changes to the chip; these changes must be managed so as
not to affect the flow conditions. It may also be advantageous to investigate
different manufacturing options such as sonic welding to remove the need
for PSA, injection, compression or transfer moulding of some parts.
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Imaging
Replacing the current camera with a low-cost option may result in the re-
quirement to introduce additional optics to improve signal quality, reduce
the effect of background light where possible, optimisation of camera set-
tings and reduction in external effects such as vibration that could reduce
image quality. A low cost light source would also need to be tested in com-
bination with the camera. Thereby, creating a complete imaging system
that would work with the prototype device.
Software automation
In terms of software improvements, more in-depth image processing could
potentially improve image quality allowing images acquired from the low-
cost imaging system to be processed. The further improvement of an algo-
rithm used to specifically identify platelet adhesion, could reduce the cost
of any potential imaging system by enabling detection from images with a
higher noise-to-signal ratio.
Diagnostic development
Although the devices were validated using whole blood response to fibrino-
gen spots and ADP, there is no limitation, in principle, to further investiga-
tions using alternative agonists of interest. The device and readout system
would remain suited to imaging and recording platelet-spot interactions in
whole blood in response to various agonists to study the efficacy of the
multitude of anti-platelet therapies.
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Platelet Surface Receptors
P2Y12 belongs to the Gi class of a group of G protein-coupled (GPCR)
receptors, it is also a chemoreceptor for adenosine diphosphate (ADP). This
receptor plays a central role in platelet activation and is the target of P2Y12
receptor antagonists. Table A.1 list a range of receptors and their ligand.
Receptor Ligand Integrin Action
GPIa/IIa Collagen α2β1 Adhesion
GPIb/IX vonWillebrand Factor -
GPIc/IIa Fibronectin α5β1 Adhesion
GPIIb/IIIa Collagen Aggregation Aggregation
Fibrinogen (secondary role
Fibronectin αIIbβ3 in adhesion)
Vitronectin
vonWillebrand factor
GPIV Thrombospondin, collagen −
GPVI Collagen Adhesion
Vitronectin Vitronectin Thrombospondin Avβ3 Adhesion
Table A.1: List of surface membrane glycoprotein receptors in blood.
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Name Usage
Bleeding time Widely used
Light transmission aggregometry (LTA) -
PFA-100 -
Flow cytometry -
VerifyNow© Used in specialised labs
Impact-R© (cone and platelet analyser) Only recently available
AspirinWorks© Increasing use
Thromboelastography (TEG) Surgery and anesthesiology
HemoStatus© Surgery and cardiology
Table A.2: Platelet function Analysis Systems
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Biological Background
B.0.5 Materials Used
All reagents were purchased from Sigma-Aldrich (St Louis,MO, USA) un-
less otherwise indicated. Device fabrication: Polydimethylsiloxane (PDMS),
(DowCorning Sylgard 184) was purchased from Farnell (Farnell Ireland,
Dublin, Ireland). Poly(cycloolefin) sheets were obtained from Ibidi GmbH
(Munich, Germany), 1.5mm thick polymethyl- methacrylate (PMMA) was
purchased from Radionics (Ireland), 50 µm and 80µm high double-sided
pressure sensitive adhesive (PSA) laminate: Arcare 8890 were purchased
from Adhesives Research (Limerick Ireland) human fibrinogen (95% clot-
table and plasminogen depleted) was purchased from Calbiochem (Merck,
KGaA, Darmstadt, Germany) and Cy3 labelled Bovine serum albumin
(BSA) was purchased from ChemQuest Limited (Wilmslow, UK). Platelet
assays: anti-CD41 mouse monoclonal antibody (clone P2, was obtained
from Immunotech, Marseilles, France), Alexa Fluor 488 labelled goat anti-
mouse and goat anti-rabbit antibodies were obtained from Invitrogen, (Carls-
bad, CA), 4.5ml Vacutainer containing 3.2% sodium citrate were purchased
from Becton Dickenson UK Limited, (Oxford, UK), adenosine Diphosphate
was obtained from BioData (Horsham, PA, USA), abciximab (ReoPro) was
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purchased from Eli Lilly and company (Indianapolis, IN, USA) and can-
grelor was from The Medicines Company (Parsippany, NJ, USA).
B.0.6 Patterning on Poly(cycloolefin) Sheet
3-Aminopropyl)triethoxysilane (APTES) functionalised poly(cycloolefin) sheets
were cut into to size and a 200 µg/mL fibrinogen solution made in 1X PBS
containing Cy3 labelled bovine serum albumin (BSA, 25 µg/mL), to aid
the visualization of the fibrinogen on the slide, was either drop coated or
µ-contact printed onto the slide surface. 50 µL of the fibrinogen solution
was drop-coated on a poly(cycloolefin) and the remaining solution was re-
moved from the sheet after incubation at room temperature for an hour.
The fibrinogen coated slide was then completely blocked with 1 % (w/v)
BSA solution. The fibrinogen solution was patterned on the slide surface
using µ-contact printing as described previously. Briefly, patterned PDMS
stamps were fabricated by pouring a 10:1 (v/v) mixture of Sylgard 184 elas-
tomer and curing agent over a patterned silicon master. After curing for
1 hr in an oven at 70oC the PDMS was removed from the master and the
PDMS stamps were inked with 50 µL of the fibrinogen solution for 30 min.
The excess fibrinogen solution was then removed from the PDMS stamp us-
ing a pipette and the stamp was dried with nitrogen. The stamp was then
placed in contact with the APTES treated poly(cycloolefin) sheet for 5 min.
After printing, the whole sheet is blocked with 1% (w/v) BSA solution in
PBS.
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B.0.7 Blood Collection and Sample Preparation
Venous blood was collected from healthy adult volunteers who had not
ingested any drugs known to interfere with platelet function for at least 2
weeks prior to phlebotomy. Blood was collected by venipuncture through
a 19-gauge needle into a 4.5ml Vacutainer containing 3.2% (v/v) sodium
citrate (Becton, Dickinson U.K. Limited, Oxford, UK). The citrated whole
blood was either loaded directly onto the device or incubated with anti-
platelet drugs. To prevent the binding of platelets to fibrinogen various
concentrations (0, 2, 2.5, 3, 4, 5, and 6 µg/mL) of abciximab (ReoPro)
were incubated with the citrated blood for 15 min at 37oC before loading
onto the device. In order to assess the effect of anti-platelet drugs, the
citrated whole blood was incubated with a final concentration of 10 µM
cangrelor for 15 min at 37oC. The agonist adenosine diphosphate (ADP),
to a final concentration of 20 µM was added to the cangrelor treated and
untreated whole blood prior to loading onto the device.
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Equations of Motion
C.1 Conservation of Mass
Consider the volume in Figure C.1 showing an idealised fixed control volume
of fluid. Since the flow through each side is considered approximately one
dimensional the conservation of mass states the change in density of the
volume over the surface plus mass flow in less the mass flow out sums to
zero or: ∫
Ω
∂ρ
∂t
dV+
∑
i
(ρiAiVi)out −
∑
i
(ρiAiVi)in = 0 (C.1)
Since the volume element is so small the integral reduces to the differ-
ential term:
∫
Ω
∂ρ
∂t
dV ≈ ∂ρ
∂t
dxdydz (C.2)
Since the mass flow acts on all six faces of the control and the the fluid
is assumed to be a continuum we can list all six flows as shown in TableC.2
Substituting these values into eqn C.1 we get:
∂ρ
∂t
dxdydz +
∂
∂x
(ρu)dxdydz +
∂
∂y
(ρv)dxdydz +
∂
∂z
(ρw)dxdydz = 0 (C.3)
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Face Inlet mass flow Outlet mass flow
x ρu dy dz
[
ρu +
∂
∂x (ρu) dx
]
dy dz
y ρv dx dz
[
ρv +
∂
∂y (ρv) dy
]
dx dz
z ρw dx dy
[
ρw +
∂
∂z (ρw) dz
]
dx dy
Table C.1: Mass flow table
Figure C.1: Control volume showing mass flow in x direction
The element volume cancels to leave:
∂ρ
∂t
+
∂
∂x
(ρu) +
∂
∂y
(ρv) +
∂
∂z
(ρw) = 0 (C.4)
Using the nabla function:
∇ = i ∂
∂x
+ j
∂
∂y
+ k
∂
∂z
(C.5)
We can rewrite the continuity equation as:
∂ρ
∂t
+∇· (ρV ) = 0 (C.6)
Which, for incompressible flow i.e. constant density, further reduces to
∇·V = 0 (C.7)
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C.2 Equations of Linear Momentum
In a simliar manner to Appendix C.1 the linear momentum equation for
Figure C.1 states:
∑
F =
∂
∂t
(∫
Ω
V ρdV
)
+
∑
(m˙iVi)out −
∑
(m˙iVi)in (C.8)
Again the volume integral reduces to:
∂
∂t
(∫
Ω
V ρdV
)
≈ ∂
∂t
(ρV )dxdydz (C.9)
The table of momentum fluxes is also constructed in a similar vein to
give
Face Inlet momentum flux Outlet momentum flux
x ρuV dy dz
[
ρuV +
∂
∂x (ρuV ) dx
]
dy dz
y ρvV dx dz
[
ρvV +
∂
∂y (ρvV ) dy
]
dx dz
z ρwV dx dy
[
ρwV +
∂
∂z (ρwV ) dz
]
dx dy
Table C.2: Table of control fluxes
Introducing these terms into eqns C.8 and C.9 we get
∑
F = dxdydz
[
∂
∂t
(ρV ) +
∂
∂x
(ρuV ) +
∂
∂y
(ρvV ) +
∂
∂z
(ρwV )
]
(C.10)
taking the term in the square bracket we can write
∂
∂t
(ρV )+
∂
∂x
(ρuV )+
∂
∂y
(ρvV )+
∂
∂z
(ρwV ) = V
[
∂ρ
∂t
+∇·(ρV )
]
+ρ
(
∂V
∂t
+u
∂V
∂x
+v
∂V
∂y
+w
∂V
∂z
)
(C.11)
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The term in square brackets can be seen to be the continuity equation
and so vanishes. The longer term in the round brackets can be seen to be
the acceleration of a particle in the control volume and can be written
∂V
∂t
+ u
∂V
∂x
+ v
∂V
∂y
+ w
∂V
∂z
=
dV
dt
(C.12)
and so eqn C.10 reduces to:
∑
F = ρ
∂V
∂t
dxdydz (C.13)
Figure C.2: Notation for stresses
Equation C.13 states the net force on the control volume must be of
differential size and proportional to the element volume. These forces are
of two types surface forces or body forces. Body forces are due to some
external force such as gravity or electrical potential however surface forces
are due to stresses on the surfaces of the control volume and are te sum of
the hydrpstatic stresses and the viscous stresses τij
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Figure C.3: Control volume showing surface forces in x direction
σij =

−p+ τxx τyx τzx
τxy −p+ τyy τzy
τxz τyz −p+ τzz
 (C.14)
The notation for which can be seen in Figure C.2 It should be noted
that it is not the stresses them sleves but rather thier gradients that cause
the net force on the control volume. This can be seen from Figure C.3 the
leftward force σxxdydz is balanced by the rightward force σxxdydz on the
right face leaving only the net rightward force (∂σxx/∂x)dxdydz. This can
be repeated for the other two directions resulting in the net force in the x
direction being given as
dFx,surf =
[
∂
∂x
(σxx) +
∂
∂y
(σyx) +
∂
∂z
(σzx)
]
dxdydz (C.15)
Substituting in values from eqn C.15 we get
dFx
dV
= −∂p
∂x
+
∂
∂x
(τxx) +
∂
∂x
(τyx) +
∂
∂x
(τzx) (C.16)
This can be repeated to give forces in both yand z
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dFy
dV
= −∂p
∂y
+
∂
∂y
(τxy) +
∂
∂y
(τyy) +
∂
∂y
(τzy)
dFz
dV
= −∂p
∂z
+
∂
∂z
(τxz) +
∂
∂z
(τyz) +
∂
∂z
(τzz) (C.17)
Combining these equations we get
(
dF
dV
)
surf
= −∇p+
(
dF
dV
)
viscous
(C.18)
where
(
dF
dV
)
viscous
= i
(
∂τxx
∂x
+
∂τyx
∂y
+
∂τzx
∂z
)
+j
(
∂τxy
∂x
+
∂τyy
∂y
+
∂τzy
∂z
)
+k
(
∂τxz
∂x
+
∂τyz
∂y
+
∂τzz
∂z
)
(C.19)
or
(
dF
dV
)
viscous
= ∇ · τij (C.20)
where
τij =

τxx τxy τxz
τyx τyy τyz
τzx τzy τzz
 (C.21)
Combining equations C.20 C.18 C.4 and by taking the gravity as the
only body force acting on the volume i.e. dFgrav = ρgdxdydz we get
ρg −∇p+∇ · τij = ρdV
dt
(C.22)
where
∂V
∂t
+ u
∂V
∂x
+ v
∂V
∂y
+ w
∂V
∂z
=
dV
dt
(C.23)
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While equation C.22 looks relatively simple but when expanded to illus-
trate the inherent complexity looks as follows
ρgx − ∂p
∂x
+
∂τxx
∂x
+
∂τyx
∂y
+
∂τzx
∂z
= ρ
(
∂u
∂t
+ u
∂u
∂x
+ v
∂u
∂y
+ w
∂u
∂z
)
ρgy − ∂p
∂y
+
∂τxy
∂x
+
∂τyy
∂y
+
∂τzy
∂z
= ρ
(
∂v
∂t
+ u
∂v
∂x
+ v
∂v
∂y
+ w
∂v
∂z
)
ρgz − ∂p
∂z
+
∂τxz
∂x
+
∂τyz
∂y
+
∂τzz
∂z
= ρ
(
∂w
∂t
+ u
∂w
∂x
+ v
∂w
∂y
+ w
∂w
∂z
)
(C.24)
If we assume incompressible flow we can use the following relationships
τxx = 2µ
∂u
∂x
τyy = 2µ
∂v
∂y
τzz = 2µ
∂w
∂z
(C.25)
τxy = τyx = µ
(
∂u
∂y
+
∂v
∂x
)
τxz = τzx = µ
(
∂w
∂x
+ ∂u
∂z
)
τyz = τzy = µ
(
∂v
∂z
+
∂w
∂y
)
to give the differential momentum equation for a Newtonian fluid with
constant density and viscosity
ρgx − ∂p
∂x
+ µ
(
∂2u
∂x2
+
∂2u
∂y2
+
∂2u
∂z2
)
= ρ
du
dt
ρgyx − ∂p
∂y
+ µ
(
∂2v
∂x2
+
∂2v
∂y2
+
∂2v
∂z2
)
= ρ
dv
dt
(C.26)
ρgz − ∂p
∂z
+ µ
(
∂2w
∂x2
+
∂2w
∂y2
+
∂2w
∂z2
)
= ρ
dw
dt
These equations are also known as the Navier-Stokes Equations
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Flow Detection Software
D.1 Software Overview
CLR
DirectShow API
C++
.net
Application Virtual Machines
Camerausb 
User Interface
Figure D.1: Block diagram showing software components used to develop image
processing software. The user interface talks with the .net framework, from inside
a virtual machine, which in turn uses the DirectShow APl to acquire images from
the camera.
Figure D.1 shown how the difference software block fit together. Direct-
Show is a multimedia framework and application programming interface
(API) produced by Microsoft and is only one part of the grater DirectX
framework. The API allows access to perform various operations with me-
dia files or streams and can be accessed via native C++ code or through
a managed framework such at .net. The DirectShow development tools
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and documentation are distributed free of charge as part of the Windows
software development kit (SDK) and is compatible with most multimedia
hardware . The .NET framework executes in a software environment, known
as the Common Language Runtime (CLR) and creates application virtual
machines that provide services such as security, memory management, and
exception handling. DirectShow allows the programmer to control every
aspect of the multimedia hardware through an instance that locks all other
software or hardware from accessing the resource.
24 bit 8 bit16 bit 2 bit 
Figure D.2: Demonstration of the effect of changing the resolution has on the
same image.
The image output is a bitmap stream of 2, 8, 16 and 24 bit pixels. A 2
bit pixel can represent only 2 colours (binary image) while a 24 bit image
in contrast has a colour depth of 16,777,216 colours for each of the three
channels red, green and blue (RGB). Figure D.2 demonstrates how detail
can be lost when the image is captured using a lower resolution, with a clear
loss in detail between 24, 16, 8 and 2 bit pixels. When the colour depth
is multiplied by the dimensions of the image the resolution and overall
file size can be calculated. The quality of any outputted image and the
time it takes to process can require a trade-off between performance and
quality and needs to be considered when designing any system, with image
resolution, processing power, memory and software all contributing to the
overall performance.
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Masking Of Image
The software uses a DirectShow compatible high definition camera to record
1 frames/s for a total on 1000s as dye was pipetted into the inlet. The
time between pipetting and the fluid starts to flow (the time to start), was
recorded. Each image acquired included the number of seconds, since the
first frame was acquired and the time was also included in the top left corner
of each image allowing for the automated detection of each frame time (t).
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Figure D.3: Example of a 24bit image being converted into a matrix. A thresh-
old is used to select which pixels should be included as part of the feature (1) or
set as background (0) within the binary matrix.
Figure D.3 shows how images were individually masked and a binary
matrix was created where zero represented a single pixel of background and
one a pixel of fluid. When an image is masked each pixel is compared to
a predefined threshold value, any pixel below that value is the background,
and given a value of 0 (Black), while pixels with a greater value will be
classed as part of the object and given a value of 1 (white). The 2 bit image
shown in Figure D.3(derived from the original 24 bit image) can be treated
as a simple matrix , making it easy to manipulate and fast to process.
D.2 Simple Channel Detection
Figure D.4-A shows two images acquired from the camera at t=n and
t=n+1. By subtracting the matrixes for time t=n from t=n+1 the num-
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Figure D.4: Conversion of image acquired from camera into a binary matrix.
A) (i) Sample image taken at t=n and masked, (ii) Sample image taken at t=n+1
and masked. From the masked images a binary matrix is produced and subtracted
to determine the np (B).
ber of pixels the fluid moved in the direction of flow was converted into a
fluid velocity. Where lp = length of a single pixel in the image. Lknown =
a known length between two points in the image measured in meters (m).
Ltotal pixels = total number of pixels between the same two points used to
calculate Lknown. Vf = fluid velocity , t = time, a = width of channel (me-
ters) and b= height (meters). The distance | AB | shown on the x axis of
Figure D.4-B yields a value for the number of pixels moved np:
np = B − A
Therefore, the length of a single pixel in meters is:
lp = Lknown ÷ Ltotal pixels (D.1)
The cross-sectional area equals:
Af = (a× b)[m2] (D.2)
The fluid velocity equals:
vf =
lp × np
t
[m]
[s]
(D.3)
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From the velocity and channel cross sectional area (Af ) the flow rate
(Q) can be calculated.
Q = vf × Af [m
3]
[s]
Q =
lp × np
t
(a× b) [m
3]
[s]
(D.4)
The height of channel (a) and width of channel (b) are also a function of
the shear rate therefore, the shear Equation 3.1 can be write as:
τw =
6µ
a2b
× lp × np
t
(a× b)
τw =
6µ
a
× lp × np
t
(D.5)
The software assumed that the inlet remained full so that there was
no effect on shear rate caused by the fluid head, while at the same time
the fluid flowed continuously from the inlet to the fluid front. The results
from the software correlated well when tested against the manual solution.
The manual solution required the operated to take measurements from a
ruler placed alongside the channel. This comparison was made by manually
checking the length the fluid had moved along the channel for each image
with that recorded from the software. The software allows for both the
manual and automated solution to be used, with the user able to manually
measure and review each image before accepting the automated results.
D.3 Complex Channel Detection
The DXF file contains a list of values (appearing one after another within
the file), the first describing the data type and the second the value assigned
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to that data type. A data type can be broadly classed as containing text
or a number, with a total of 1071 used to declare a wide range of objects
from the X (20) value of a data point to the colour of a line (62). The sub-
section ACDbPolyine, contained within ENTITIES, stores a list of vertices
and bulges used to create a closed polygon. To demonstrate how effective
this system is, a section of text from a DXF file encompassing a single
ACDbPolyine is reproduced in Figure D.5.
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Figure D.5: DXF file section describing a polyline. i) Sample showing how
a point and bulge can be described within a DXF file. ii) Part of a DXF file
containing the [ACDbPolyine] for a sample shape, with the first three codes
containing information about the polyline (90, 70 and 43). While the rest of the
text contains the vertices (points) used to draw the shape.
The sample polygon shown in Figure D.5 consists of a 10 × 10 square
and a single bulge from point C to D. Once the polygon is set-up the point
A is introduced as the start of the polygon before B and C are declared.
The start point of the bulge is the last declared point (in this case C) while
the end point is included within the bulge declaration. The bulge is the
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tangent of one fourth the included angle for an arc segment, made negative
if the arc goes clockwise from the start point to the endpoint. A bulge of
0 indicates a straight segment, and a bulge of 1 is a semicircle. The bulge
shown in Figure D.5 is a semicircle and the closed polygon [A, B, C, D,
A] is drawn clockwise, therefore the value for this bulge (data type 42) is
-1. Once the value equals ENDSEC the ACDbPolyine has ended (when
the polygon is closed) the last point and first point are the same, when the
closed flag is set to 1 within the polygon definition. Once the polygon has
been extracted from the file the user can scale the shape to fit over the
channel using software developed to determine the flow rate.
DXF Stencil
DXF stencil 
a
b
User Interface Used To
 load a DXF file and 
setup the stencil
Inlet
Figure D.6: User interface and sample DXF stencil.
Once the polygon has been extracted from the file a rectangle is drawn
around the polygons extent to define the minimum required area for a given
stencil, this area is used to crop the image. The stencil defines the area
within the channel that can be filled with fluid. Figure D.6 shows a sample
stencil for a channel with a single inlet, alongside a user interface used to set-
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up the stencil. From the user interface the channel can be scaled, rotated,
inverted and coloured to make it easier to see against differed backgrounds.
Figure 3.5 shows how the stencil can be placed over the image acquired for
the camera and a series of regions extracted.
154
Appendix E
Mini Individual Platelet
Adhesion (MiPA) Unused
Chip Designs
E.1 Movement Of Rocking Table
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Figure E.1: Rocking table oscillation ± 16o.
The movement of the rocking table was also recorded using software
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developed in Java, with the sensors available on a smart phone. Figure E.1
show the table top moving through a full oscillation, starting at 16o before
the table returned to the flat (0o), moving through to −16o before returning
back to −16o. Data was recorded for 5 minutes at a number of different
oscillations per minute and showed smooth, reproducible, oscillations across
all speeds tested. Using the accelerometer sensor a maximum acceleration
of 0.05 m/s2 was recorded for a speed of 30 oscillations per minute rising
to 0.15 m/s2 for 100 oscillations per minute, all data was recorded at the
centre of the table. A height of 0.85 mm was calculated for a volume of 50 µl
of blood 0o, a minimum height of 0.22 mm was calculated at ± 16o. This
change in height was expected as the blood is only flowing with the aid of
gravity (see Section 2.1.3) and as 50 µl was already selected a low volume
and high volume (maximum fluid height of 0.73 mm) well was tested to
determine if the change in height would affect the resulting % of occupied
spots.
E.2 Comparison of Substrates Used With iPA
A comparison was made between the optimised MiPA and iPA assays on
both a glass and zeonor substrates to determine if there was a difference be-
tween the % platelet adhesion across the two assays. The Zeonor substrate
was tested as it has a number of advantages over the glass substrate cur-
rently used, its low cost, availability in any size, ability to be cut to shape,
optical properties and the removal of any possible sharps injury (associated
with glass) make it ideal for use in a point-of-care device.The Health Service
Executive (HSE) requires that any new devices meet certain requirements.
The term “sharp safe” refers to the removal of any glass or needles that by
cause injury from the device. The results from Figure E.2-A and B indicate
Zeonor can be substituted for glass without any significant fall off in perfor-
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mance across both assays, there was also a smaller % adhesion achieved by
the MiPA on both substrates when compared to iPA. This difference may
be explained by the volume of blood used for each assay, or as a result of
the way the blood moves across the surface.
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Figure E.2: Comparison of substrates used in both MiPA and iPA. (A) Com-
parison of glass and Zeonor to determine if a change in substrate material would
have a meaningful effect of % platelet adhesion, no significant difference between
the two was recorded, with a smaller % adhesion when MiPA is compared to iPA.
The glass cover slid and glass slide used, with the area of printed 6 µm spots (in
red) is also shown.
E.3 Integrated Chip Designs
The gen1 closed chip consists of seven layers, three of PMMA, three PSA
gaskets used to create the well assembly (layers 2, 3 and 4) and filling
assembly (layers 5, 6 and 7 ) and one Zeonor substrate (Figure E.3). The
two sub-assemblies are adhered together before the monovette connector (8)
and Zeonor substrate (1) are added to create a fully assembled chip. The
blood passes through the connector which is secured in place between layers
7, 6, and 5 before passing into the channels within the filling layer (4), the
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Figure E.3: First generation closed chip layers. Seven layers make up the
closed version of the gen1 chip starting with the Zeonor layer cut to size from
a bigger sheet, (2) pressure sensitive adhesive (PSA) gasket between the Zeonor
and the assay wells, (3) assay wells laser cut from PMMA, (4) PSA filling layer,
(5) PMMA spacer layer, PSA gasket between spacer and top layer, (7) PMMA
top layer, (8) monovette connector, (9) monovette syringe. The assembled chip
is also shown with the transparent PMMA layer and the white PSA gasket and
filling layer along the syringe.
two nearest wells are filled first before the blood starts to fill the next two
wells, once all wells are full the chip was rocked for 30 minutes. The initial
results showed zero % platelets adhered to the 6 µm spots indicating that
further optimisation of blood volume may be required.
Version 1
The First of these is shown in Figure E.4 and is made up of 6 layers with a
PSA gasket between each one, unlike the gen1 closed chip the fill layer was
made from PMMA along with layer 1, 2, 4, and 5. A green dot shows where
fluid passes from one layer to another through the delivery layer into the
assay wells below and into the volume indicator wells located to the right
of the chip. The fluid enters the filling layer and starts to fill the four well
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Figure E.4: Version 1 of the second generation design. The layers shown exclude
the PSA gasket between each. As the connecter was moved to the side of the
chip an additional spacer layer was required. The progress of flow is also shown,
starting as the blood leaves the connector and moves along the filling layer before
reaching the inlets into the assay well and indicator well at the same time, with
the 10 µl filled by the first indicator well and 20 µl of blood added to the assay
well by each subsequent well filled.
channels along with the volume indicator channel with the fluid reaching the
end of the well channels and the first indicator well at the same time, as the
volume of fluid each channel can hold is equal. At this point the fluid passes
through the delivery layer and into the wells below with the first indicator
well holding 10 µl and each subsequent indicator well holding 20 µl of fluid
the user can deliver fluid in increments of 20 µl to the assay wells. This
difference is to account for the length of channel the fluid must move before
reaching the next indicator well, resulting in a maximum possible user error
of 10 µl between each indicator well.
When this design was tested with water the overall performance was
excellent with each well filling with the same volume of fluid. However,
when whole blood was introduced its increased viscosity caused it to favour
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filling the indicator channel over the assay wells as there was no need to pass
through the holes within the delivery layer to reach the assay wells. Even
when these holes were increased in size there was no improvement to chip
performance with the assay wells only beginning to fill when the indicator
channel had nearly completely filled with blood. To address these issues the
chip was redesigned and a holding well introduced as the blood exited the
connector.
The gen1 chip introduced the intergraded monovette connector for load-
ing of the sample directly from a syringe through a PSA filling layer within
the chip. When the connector was inserted into the chip it would tend to
touch the PMMA layer below causing the chip to delaminate and blood to
leak between the layers of the chip. The 50 µm filling layer made adjusting
the height of the connector which was simply pushed into place in such a
way as to prevent delamination and allow the blood to flow into the fill layer,
without additional leaking around the inlet from a loose fit. There was also
a difficulty associated with laser cutting the smaller features around where
the blood flowed into the assay wells. The results from the gen1 chip show
a number of important shortcomings in its design, in terms of volume de-
livery, fluid flow and manufacturability of a first stage prototype. The chip
created a good foundation for the development of the second generation of
chips with a requirement to further optimise of fluid flow within the assay
well in an effort to increase % adhesion and a method to deliver the required
blood volume to the assay well all within the confines of a closed chip.
Version 2
By moving the connector to the top of the chip from the side the need for
a spacer layer was removed, this reduced the chance of leakage around the
connector, materials used and the overall assembly time as an interference
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Figure E.5: Version 2 of the second generation design. The layer shown excludes
the PSA gasket between each. The connector has been placed at the top of the
chip removing the need for a spacer layer. The progress of flow is also shown,
starting as the blood enters the holding well reaching the inlets into the delivery
layer at the same time, before moving along the filling channels to the outlets of
the delivery layer and faintly into the assay wells.
fit could be used. The holding well is an important component of this
design and allows for blood to be delivered to the four filling channels and
the indicator channel at the same time with an equivalent resistance to
flow. As the fluid fills the holding well it remains level filling the bottom of
the well first, with the viscosity of the fluid preventing it from entering the
delivery layer before the well is completely full (Figure E.5). As the filling
well is ten times the size of the outlet within the delivery layer the hydraulic
force acting on each outlet is equal (assuming equivalent resistance to flow
through each outlet) causing each channel to fill at the same rate. The fluid
is now free to fill each assay well with the same volume as that within the
indicator channels with a minimum delivery of 35 µl of fluid. This design
performed very well with water but again experienced issues with some
blood samples as air within the sample prevented the holding channel from
filling completely or in some cases bubbles blocking the outlet. If additional
force was applied to the syringe the bubbles could be displaced with the
effect that some wells would fill more than others, making the indicator a
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useless guide.
Many of the features found within the earlier iterations of the chip can be
see within the final chip design. Figure shows the layers for three versions
of the chip, with the smaller rectangular well used for these designs.
Version 6 
Version 5 
Version 4 
Figure E.6
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F.1 Blob Analysis
Blob analysis allows for each object or region within an image to be individ-
ually identified according to a predefined threshold. An analysis technique
is applied to a given image to determine which pixels make up the object,
a blob is therefore a list of these pixels. The blob its self has no properties
and requires further post-processing before any useful information can be
determined. Laplacian (Laplace) of Gaussian (LOG) is one of the most
commonly used technique, a Gaussian blur is first applied to the image be-
fore the Laplace filter can be applied. The Laplace filter is less sensitive to
noise if the image is first blurred, without the blur many small blobs can be
created thereby taking pixels away from the objects within the image and
creating many useless fragments. The Laplacian L(x, y) for a given image
with pixel intensity values is given by:
L(x, y) =
∂2I
∂x2
+
∂2I
∂y2
(F.1)
A convolution kernel can be used to approximate the second derivatives
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within Equation F.1 using:
0 −1 0
0 4 −1
0 −1 0


−1 −1 −1
−1 8 −1
−1 −1 −1
 (F.2)
Equation F.2 convolution show two commonly kernels used discrete ap-
proximations to the Laplacian filter, started in the left corner the kernel is
slid over the image as to move through all positions within a given image.
Each kernel position corresponds to a single output pixel, the value of which
is calculated by multiplying together the kernel value and the underlying
image pixel value for each of the cells in the kernel (Equation F.3).
I =

III I12 I13 I14 I15 I16 II7
I2I I22 I23 I24 I25 I26 I27
I3I I32 I33 I34 I35 I36 I37
I4I I42 I43 I44 I45 I46 I47
I5I I52 I53 I54 I55 I56 I57
I6I I62 I63 I64 I65 I66 I67

K =

KII KI2 KI3
K2I K22 K23
K3I K32 K33

(F.3)
Using the image matrix (I) and kernel matrix (K) (shown in Equa-
tion F.3) an output pixel P can be calculated , take I45 as an example:
O45 =I45K11 + I46K12 + I47K13 + I55K21 + I56K22 + I57K23
+ I65K31 + I66K32 + I67K33
(F.4)
If the image has M rows and N columns, and the kernel has m rows and
n columns, then the size of the output image will have M − m + 1 rows,
and N − n+ 1 columns, allowing the convolution to be written as:
O(i, j) =
m∑
k=1
n∑
l=1
I(i+ k − 1, j + l − 1)K(k, l) (F.5)
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where i runs from 1 to M - m + 1 and j runs from 1 to N - n + 1.
As the Kernels are approximating a second derivative measurement on
the image they are very sensitive to noise. While the Gaussian smoothed
can be performed separately it is possible to combine both the equations
and thereby Increase the performance of an image processing system as only
a single calculation is required per pixel (Equation F.6).
LoG(x, y) = − 1
piσ4
[
1− x
2 + y2
2σ2
]
e−1−
x2+y2
2σ2 (F.6)
Equation F.6 can also be approximated by a 7× 7 kernel. For most real
time image processing applications the kernel is typically slid to all pixels
within the array, this will result in no corresponding value for some kernel
positions at the edge of the image. However, as no values are available for
the rest of the kernel (now outside of the image) there can be some distortion
at the side and bottom edges of the output. It is however beneficial to use
all positions within the array, as the resulting output image is of the same
size.
By applying a zero crossing detector to the output it is possible to cre-
ate a binary image highlighting features. A zero crossing detector looks for
places in the Laplacian output of an image where the value of the Lapla-
cian passes through zero (change in sign). These changes occur in an area
where there is a big difference in intensity and normally denote the edge
of an object, but this is not always the case and requires additional post-
processing to determine which feature can be treated as a blob or which
feature is noise. From the output image it is possible to determine different
blob features including the object area, centre of gravity, rectangle size and
if the blob is a standard shape. The iPlatelet software uses basic filters
adapted from the AForge .net framework available under General Public
License (LGNU V3).
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The result of applying a Gaussian blur, to a region of an image containing
platelets adhered to a surface is shown in Figure F.1-B. While the blur has
the effect of removing noise and thereby limiting the number of features to be
investigated, there are three platelets missing from the output (highlighted
within the red boxes). As these platelets have a low intensity the blur moves
these pixels into the same value range as a background pixel. Although these
platelets are somewhat visible in Figure F.1-A, there is also a lot of noise
visible making the output difficult to work with. Figure F.1-C attempts to
solve this problem with the addition of two pre-processing filters. First a
scaling filter is applied to increase the intensity of each platelet, before a
mid-pass filter (MPF) is applied to the input image. By setting any pixel
below a set value to 0 and any value above a set value to a pre-defined
maximum the MPF filter can reduce noise and decreases the intensity of
platelets that may saturate the image.
While two of the three platelets are now visible, within the red box in
Figure F.1-C, the filters were unable to detect the platelet of the lowest
intensity. For the iPlatelet software the lower boundary of the MPF was
reduced to allowing non-platelet features to be included within the output,
thereby requiring a feature selection step to be added in post-processing.
F.1.1 Spot Region Detection
The rotation of the stamp during the µ-contact printing process does not
affect the results when calculating the % occupancy, when using the matched
feature methods. However, as SLD only needs a single image there is no
way to determine if a spot is missing or badly-printed without a pre-defined
reference, required to match the expected location of each point within
the array to a blob extracted from the input image. By using the four
crosses encapsulating a 13 × 13 array of spots as processing markers, the
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Appendix F. Detection Software Principles
Image as taken from camera
Image after Gaussian blur 
Resulting threshold image 
used for edge detection Edge detection result
A
B
Image after Scaler +MPF  
+ Gaussian blur 
   
C
Figure F.1: The effects of applying a Gaussian blur to a sample region of a
platelet image. 1. Unfiltered region, 2. region after Gaussian blur, 3. region
after Gaussian blur, scaling filter and mid-pass filter (MPF) is applied. The
effects on the output image are shown when both a threshold filter and edge
detection are applied, with an area of the bottom left hand corner (highlighted
in red) used to demonstrate some common issues with blob detection.
rotation of the array and therefore the expected location of each spot, can
be calculated. Figure F.2-A shows the 13 × 13 array at 00 and rotated by
and angle θ and the four process markers surrounding it. As the arrays are
printed next to each other a marker is shared by up to four arrays of spots
requiring the software to process 1 to n number of arrays within a single
image. The centroid for each of the four crosses is first determined and an id
is assigned (a, b, c and d), using these four centroids a centre point (O) for a
given array can be calculated. By determining the angle between two lines,
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Figure F.2: Details how a mesh is built and fitted to an input image to account
for image rotation. A) shows two arrays of spots along with the crosses used as
image processing markers, with one array rotated by an angle θ. B) illustrates the
lines used to calculate the rotation and therefor the spot locations, an associated
mesh is also shown and numbered. C) demonstrates how a mesh is laid over the
input image to extract the region around each spot.
starting at each of the four markers and intersecting at the centre point O,
both the rotation and quality of the resulting mesh can be calculated. If
one of the four markers has not been correctly printed or is not fully shown
within an image, the centre of gravity for the marker will move resulting in
the array failing quality checks and being excluded from the calculated %
occupancy. The resulting mesh is shown in Figure F.2-B and is made up of
a grid with each intersection representing a the location of a spot, the mesh
is built in real time for each image thereby automatically being scaled for
the magnification used with the microscope.
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